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 A palladium-catalyzed cycloisomerization of 1,6-enynes, which 
can provide a variety of cyclic compounds, has been studied, The 
reaction pathway is highly dependent upon a leaving group of 1,6-
enynes. Enynes with a phosphate leaving group gave rise to 5.7-
bicyclic trienes and by an alkoxy group yielded monocyclic trienes. 
We also observed a Pd(∏)-catalyzed cycloisomerizaiotn of 1,6-
enynes to bicyclo[4.1.0]heptenes in good yields under optimized 
conditions. 
 
Keywords: Palladium, Catalysis, Trienes, Bicyclo[4.1.0]heptenes, 























The transition metal-catalyzed cycloisomerization reactions have 
attracted a great deal of attention1 because they can easily provide a 
variety of cyclic compounds.2 For example, cyclopropyl groups 
engage in many rearrangement reactions including a 
vinylcyclopropane rearrangement and a divinylcyclopropane-
cycloheptadiene rearrangement.3 Cyclopropyl groups also participate 
in cycloaddition reactions such as a formal [5+2] cycloaddition.4 
Vinyl cyclopropanes (VCPs) are considered to be particularly 
suitable C5 building blocks in the formal [5+2] cycloaddion. Thus, a 
variety of transition-metal-catalyzed cyclizations have been 
developed over the past decades.5 In particular, Wender6 has 
demonstrated that VCP is a very versatile strained cyclic synthon in 
the rhodium-catalyzed [5+2] cyclizations of cyclopropylen-ynes. 
However, the reaction products in the transition-metal-catalyzed 
reaction of cyclopropylen-ynes seem to be rather dependent upon a 
catalyst and the identity of the substituent on the alkyne. For 
example, Louie et al. found7 a size effect, due to the substituent on 
the alkyne, on the heterocyclic product formed in a Ni(COD)2/SIPr-
catalyzed reaction, although employment of Ni(COD)2/ItBu as a 
catalytic system solved the selectivity problem (Scheme 1). Pimm 
reported8 the formation of alk-1-enyl-(3-
aza)bicyclo[3.1.0]hexanes in the palladium-catalyzed cyclization of 
olefinic propargylic carbonates. Recently, we reported8 that a 
consecutive reactions of platinum- and rhodium-catalyzed 
cycloisomerization of enynes bearing a cyclopropyl and aryl group in 
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the alkene and alkyne termini, respectively, afforded 

























Scheme 1. Metal-catalyzed cycloisomerization 
 
Based on the previous studies, we envisioned that palladium-
catalyzed cyclization of cyclopropyl-substituted 1,6-enynes 
proceeded in two ways depending upon the presence or absence of a 
leaving group. In the presence of the leaving group, 5.7-bicyclic 
trienes were obtained as the sole product; in the absence of the 
leaving group monocyclic trienes were isolated [Eq. (1)]. Based on 
the experimental observations, a plausible reaction mechanism for 




















































when R' = H or D







R' = H, D, Me
X = NTs
 
Scheme 2. Proposed mechanism for the Pd catalyzed formation of 5.7-
Bicyclic Trienes 
 
 Next, we tested whether 3 (1-((E)-buta-1,3-dienyl)-2-
methylenecyclopentane) undergo Dielse-Alder reacation with 
maleimide(dienophile). However, when 3 (0.3 mmol) was treated 
with 5 mol% Pd(OAc)2, 10 mol% PPh3, and 1.3 equiv maleimide in 3 
mL 1,4 – dioxane at 90oC, no Diels-Alder-type product was isolated. 
Instead, a bicyclo[4.1.0]heptene compound (4) was isolated in 40% 
yield [Eq. (2)]. To the best of our knowledge, there has been no 
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report on the formation of bicyclo[4.1.0]heptenes in the presence of 
palladium catalysts. The formation of bicyclo[4.1.0]heptenes has 
been recognized for Pt,9 Au,10 Ir,11 and Rh12-catalyzed 





Typically, cyclizaion of 1,6-enynes in palladium system proceeded  
5 –exo type cyclization. Thus, the palladium-catalyzed formation of 
bicyclo[4.1.0]hept-2-enes is unprecedented. So, we proposed a 

























































Results and Discussion 
 
1. Palladium-Catalyzed Cyclization of Cyclopropyl-Substituted 1,6-
Enynes to 5.7-Bicyclic Trienes or Monocyclic Trienes Depending 
Upon a Leaving Group. 
Initial treatment of olefinic propargylic diethyl phosphate 1 with a 
catalytic amount of [Pd2(dba)3] in dioxane at 90 °C for one day gave 
bicyclic triene 1a in 17% yield with 67% recovery of the reactant 
(Scheme 2). The structure of 1a was confirmed by 1H and 13C NMR 
studies. It has a 4-methylene-1,2,3,4,5,6-hexahydroazulene 
skeleton, which can be considered to be an important building block 
because it may participate in a variety of functionalizations and 
tandem carbon–carbon bond-forming processes. The formation of 
1a suggests that the phosphate acts as a leaving group. Encouraged 
by the observation of the formation of 1a, we also screened other 
palladium compounds (Table 1, entries 1–8). Among them, the best 
yield (81%) was observed in the presence of 5 mol% Pd(OAc)2/10 
mol% Ph3P in dioxane for one hour. The yield of the reaction was 
highly sensitive to the reaction medium (entries 9 and 10). We also 
screened nickel compounds such as Ni(acac)2/Ph3P (1:2) and 
Ni(OAc)2/Ph3P (1:2) as potential catalysts. However, no reaction 
was observed with the nickel systems. We were able to establish the 
following optimized reaction conditions: 5 mol% Pd(OAc)2, 10 mol% 








Entry catalyst Solvent Temp(oC) Time (h) Yield (%)c 
1a Pd2(dba )3 Dioxane 90 24 17 
2a Pd(PPh3)4 Dioxane 90 24 42 
3a Pd(OAc)2 Dioxane 90 24 13 
4a Pd(OAc)2/dppp(1:1) dioxane 90 24 28 
5a Pd(OAc)2/dppp(1:1) dioxane 25 24 41 
6a Pd(OAc)2/dppe(1:1) dioxane 70 2 71 
7a Pd(OAc)2/P(o-toly)3(1:2) dioxane 80 24 23(52)
d 
8b Pd(OAc)2/PPh3(1:2) dioxane 100 1 81 
9b Pd(OAc)2/PPh3(1:2) DCE 90 22 33 
10b Pd(OAc)2/PPh3(1:2) toluene 90 1 39 
11b,e Pd(OAc)2/PPh3(1:2) THF-
MeOH 
70 21 63 
12b Ni(acac)2/PPh3(1:2) dioxane 90 24 n.r.
f 
13b Ni(OAc)2/PPh3(1:2) dioxane 90 24 n.r.
f 
[a] Reaction conditions: Pd catalyst (10 mol%), enyne (0.22 g, 0.5 mmol), solvent (5 mL). 
[b]. Reaction conditions: Pd catalyst (5 mol %), enyne (0.22 g, 0.5 mmol), solvent (5 mL). 
[c]. Isolated yield. 
[d] .Yields in parenthesis are the reactant recovered. 
[e] .Reaction conditions: enyne (0.22 g, 0.5 mmol), Pd(OAc)2 (5 mol%), THF (5 mL), 
MeOH (0.5 mL), CO (1 atm). 










We first examined whether the phosphate was the best leaving 
group or not under the optimized reaction conditions (Table 2). 
Olefinic propargylic compounds (entries 2 and 3) having an acetoxy 
or carbonate as a leaving group afforded the expected 1a in rather 
lower yields (40% and 49%, respectively) under our reaction 
conditions. In the case of the carbonate, when the reaction was 
carried out in the presence of 5 mol% Pd(OAc)2 and 5 mol% dppp 
under 1 atm of CO, a higher yield (63%) was observed. The leaving 
group has a dramatic effect on the yield of the reaction and the best 
yield (81%) was observed with the phosphate group. Therefore, we 
examined the scope of substrates bearing a phosphate group under 
our reaction conditions. As the steric bulkiness of N-tether groups 
increased (entry 4 vs 5), the yield decreased. The number of 
internal substituents (entry 6 vs 8) and the identity of the 
substituents (entry 6 vs 7) affected the yield of the reaction. The 
use of a 1,7-enyne substrate did not affect the reaction (entry 9). A 
carbon-tethered substrate (entry 10) also underwent the reaction. 
When a substrate (11) was treated in dioxane in the presence of the 
standard catalytic conditions, a monocyclic triene (11b), 1-((E)-








Table 2 Palladium-Catalyzed Cyclization of Cyclopropyl-Substituted 1,6-Enynes to 5.7-
Bicyclic Trienesa 





1 1 R = PO(OEt)2 1 1a 81 
2 2 R = COMe 1 1a 81 















6 6 R = Me  20 6a 93 
7 7 R = Et 4 7a 60 













 10  10a 47 
[a] Reaction conditions: substrate (0.3 mmol), Pd(OAc)2 (5 mol%), Ph3P (10 mol%), 





























Zuo and Louie reported5a a similar reaction in the presence of 
Ni(cod)2/NHC. To ascertain whether this rearrangement was typical, 



















Scheme 4 Palladium-catalyzed cyclization of cyclopropyl-substituted 






5 mol % Pd(OAc)2















5 mol % Pd(OAc)2
10 mol % PPh3
5 mol % Pd(OAc)2
10 mol % PPh3
Dioxane, 90 oC
Dioxane, 90 oC
12 12b 42% (20 h)
13 13b 67% (24 h)
14 14b 65% (1.5 h)
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With substrate 12 containing the cyclopropyl group, monocyclic 
triene 12b was isolated in 42% yield. With a phenyl (13) or methyl 
group (14) instead of a cyclopropyl group, monocyclic dienes 13b 
and 14b were isolated in 67 and 65% yields, respectively. Thus, the 
formation of cyclopentane derivatives was quite general for the 
palladium-catalyzed reaction of enyne substrates not bearing a 
leaving group. In the formation of a bicyclic triene from a substrate, 
both the leaving group and one of the hydrogen atoms were lost. To 
gain some information on the formation of bicyclic trienes, 
deuterated compound 1-D was reacted under the standard reaction 
conditions [Eq. (3)]. When the product of the reaction was isolated, 
the deuterium was not found in the product. This observation 
suggested that the disappearing hydrogen atom was from the inner 





5 mol % Pd(OAc)2
10 mol PPh3
dioxane, 90 oC
1-D 1a 81% (1.5 h)  
 
Moreover, when a methyl group was introduced into the same 
position as that of the deuterium in 1-D, a new cyclopentene 
derivative, 15c, produced by the isomerization of an allene to a diene, 
instead of a bicyclic triene, was isolated in 60% yield [Eq. (4)]. A 
similar reaction product was obtained in the palladium-catalyzed 
carbocyclization of aza-enallenes.13 It seems that the presence of a 
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5 mol % Pd(OAc)2
10 mol PPh3
dioxane, 90 oC
15 15c 60% (17 h)  
 
Based on the experimental observations, a plausible reaction 
mechanism for the formation of a has been proposed (Scheme 2). In 
the presence of a palladium catalyst, an equilibrium mixture of η1-
allenic and propargylic intermediate I forms,13 which may be in 
equilibrium with η3- propargyl intermediate II.14 Both intermediates 
can be transformed into a (π-olefin)(σ-allenyl)palladium 
intermediate III. Carbon–carbon bond formation followed by ring-
opening of the allyl group leads to intermediate V. The allyl group 
then attacks the central carbon of the allene group to form a seven-
membered ring and regenerate the catalytic species to reenter the 





2. Palladium-Catalyzed Cycloisomerization of Enynes to 
Bicyclo[4.1.0]hept-2-enes. 
 Our initial study began with a reaction of an enyne (1a) in the 
presence of 5 mol% Pd(OAc)2 and 10 mol% of PPh3 in 1,4-dioxane 
at 90oC. After work-up, a monocyclic triene compound (1b) was 
isolated in 40% yield. In order to use the in situ generated triene in 
the Diels-Alder-type reaction, 1.3 equiv maleimide was added from 
the beginning. However, no Diels-Alder-type product was isolated. 
Instead, a bicyclo[4.1.0]heptene compound (1d) was isolated in 40% 
yield. As far as we are aware, this was the first observation of the 
formation of bicyclo[4.1.0]heptene in the palladium-catalyzed 
cycloisomerization of 1,6-enynes. When the same substrate was 
reacted in the presence of 10 mol% PtCl2 in 1,4-dioxane at 90
oC for 
1 h, 1d was obtained in 45% yield. Although maleimide did not 
participate in the reaction product, it had to play some role in the 
reaction. In order to obtain a maximum yield of 1d, we optimized the 
reaction conditions, including the palladium precursor, the additive 
(ligand), the reaction solvent, the reaction temperature, and the 
reaction time (Table 1). The use of Pd(OAc)2 as a catalyst in the 
presence of PPh3 afforded 1b in low yield (25%) (entry 1). When 
Pd2(dba)3 was used as a catalyst precursor in dioxane, no reaction 
was observed (entry 3). Our screening showed that the use of an 
additive: Pd ratio of 1: 4 was found to be optimal for this catalytic 
system.15 When Pd(PPh3)4 in presence of maleimide was used as a 
catalyst in toluene at 90oC for 16 h, 1d was isolated in 62% yield 




Table 3. Palladium-catalyzed cycloisomerization of 1,6-enynes 16 and 17 
 
 
























dioxane 90 24 0 0 




dioxane 90 24 9 0 




toluene 90 16 62 0 




dioxane 90 48 0 40 




toluene 90 20 44 0 




toluene 90 24 0 0 




toluene 90 24 0 10 




toluene 90 24 0 29 





toluene 90 16 0 16 





toluene 90 5 0 37 
12 Pd(maleimide)
2(PPh3)2 (10) 
- THF 50 7 9 0 
13 Pd(maleimide)
2(PPh3)2 (10) 
- DCE 70 7 6 82 
14 Pd(maleimide)
2(PPh3)2 (10) 






























- toluene 130 7 60 40 
16 Pd(maleimide)
2(PPh3)2  (10) 
- xylene 150 7 17 18 
17 Pd(MeCN)2Cl
2(10) 




















































xylene 150 7 0 30 
[a] Entries 1-15 used compound 16. [b] Pd(C4H2NO2)2(PPh3)2 was prepared according to the 




When succinic imide was used instead of maleimide in toluene, 1c 
was isolated in 44% yield (entry 6). Interestingly, when imidazole 
(entry 7) or N-phenylmaleimide was used instead of maleimide, no 
reaction was observed. Moreover, when benzoquinone, furan-2,5-
dione, cyclopent-4-ene-1,3-dienone, or 1,2-cyclohexanedione 
was used instead of maleimide (entries 8-11), only 1b was isolated 
in low yields (10 %, 29 %, 16 %, and 37% yields, respectively). 
These observations suggested that maleimide acted as a ligand to 
produce a Pd(II) species, Pd(maleimidate)2(PPh3)2 (maleimidate = 
C4H2NO2). Thus, Pd(C4H2NO2)2(PPh3)2 was prepared and used as a 
catalyst in the reaction. Using Pd(C4H2NO2)2(PPh3)2 as a catalyst, 
the reaction solvent was screened (entries 12-16). The reaction 
was highly dependent upon the solvent and the best result was 
obtained in toluene. Thus, we established the optimum reaction 
conditions as follows: 10 mol% Pd(C4H2NO2)2(PPh3)2 (or 10 mol% of 
Pd(PPh3)4 and 40 mol% of maleimide) in toluene at 130
oC for 7 h. 
We also had to find another set of optimum reaction conditions 
because the established reaction conditions were not good enough 
for some substrates. For example, when (E)-N-(3-
cyclopropyallyl)-4-methyl-N-(pent-2-yn-1-
yl)benzenesulfonamide, 2a, was used as a substrate, 2c was isolated 







17d (40 %)  
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Thus, we had to find another set of optimum conditiona to obtain 
the maximum yield of 2c. We examined Pd(MeCN)2Cl2 with 
phosphine or phosphite as catalyst (entries 17-25) for Eq 2 
because Pd(MeCN)2Cl2 has been widely used as a palladium(II) 
catalyst or precursor in diverse catalytic reactions.17 When 
Pd(MeCN)2Cl2 was used as a catalyst in the absence of any additive 
(entry 17), no reaction was observed. However, in the presence of 
phosphite or phosphine, a mixture of 2b and 2c in various ratios was 
isolated (entries 18-22). Among the phosphines and phophites used, 
the best result was observed with P(OPh)3. We attempted to 
synthesize [Pd{P(OPh)3}2Cl2] and use it as a catalyst. However, it 
was too hydrophilic to isolate. Thus, we had to use Pd(MeCN)2Cl2 
with P(OPh)3 (1: 4) as catalyst. We also examined the effect of 
solvent on the yield of 2c (entries 18 and 23-25) and discovered 
that the yield of 2c was highly sensitive to the solvent. The best 
result was observed in toluene (entry 18), but, strangely no reaction 
was observed in DCE or dioxane (entries 23 and 24). We also 
examined a diphosphine such as BINAP as an additive in the 
presence of Pd(MeCN)2Cl2. However, we failed to isolate a major 
product because there were too many spots in the tlc plate. Thus, 
we established two sets of optimal reaction conditions using 
Pd(C4H2NO2)2(PPh3)2 and Pd(MeCN)2Cl2 with P(OPh)3 (1: 4), 
respectively, and could use one of them according to the substrate. 
We next examined the scope of a substrate under our optimal 
reaction conditions (Table 2). Most substrates gave rise to 
bicyclo[4.1.0]hepenes as single diastereomers in reasonable to high 
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yields. An Alder-ene-type reaction may take place in some cases 
(entries 18, 20, and 21). Fortunately, the formation of an Alder-
ene-type product (b) was not observed in the other cases. When 
the yield of d was not good enough, no isolable major compounds 
were formed. The yield of d was highly dependent upon the 
substituent on the alkyne and alkene moieties. Enynes with a 
terminal alkyne (entry 18), or with a sterically bulky substituent on 
the alkyne (entry 31) were poor or inert substrates under our 
reaction conditions. When enynes (entries 31-34, 38, and 40) 
having a cyclopropyl group at the terminal position of an olefin were 
used as a substrate, the yield was highly sensitive to the substituent 
at the terminal position of an alkyne in the following order H << 
cyclohexenyl ≈ Et < CH2OMe < Me <cyclopropyl. In the case of 
enynes (entries 13-19) bearing a 4-MeOC6H4 group at the terminal 
position of an olefin, the yield was highly sensitive to the substituent 
at the terminal position of an alkyne in the following order cyclobutyl 
< C6H4-OMe-4 < 
nPr ≈ Me < cyclopropyl < Et. For enynes (19, 20, 
21, and 28) with a methyl group at the terminal position of an alkyne, 
the yield was highly sensitive to the substituent at the terminal 
position of an alkene in the following order Me < Ph < cyclopropyl ≈ 
4-MeOC6H4. Substrates 19 and 22 having a methyl and a 
cyclopropyl group at the different terminal positions of an alkyne 
and an olefin, gave quite different yields (72% and 53% yield, 
respectively). Enynes (entries 35 and 37) having an aryl group at 
the internal carbon of the olefin moiety were better substrates than 
those (entries 24 and 28) bearing an aryl group at the terminal 
22 
 
position of an olefin. In the cases of enynes (entry 35 vs. 36; 37 vs. 
38) having an aryl group at the internal carbon of the olefin moiety, 
the electronic effect of a substituent on the aromatic ring might 
exert on the yield: an electron-withdrawing group diminishes the 
yield of a reaction. Interestingly, a compound having a 
cyclopenta[c]pyridine skeleton was obtained in 41% and 31% yields, 










The same kind of transformation was previously found18a in the 
consecutive reactions of a PtCl2-catalyzed cycloisomerization of 
dienynes having a phenyl group at the terminal carbon of an alkene 
moiety, followed by vinylcyclopropane rearrangement. The structure 
of the bicyclo[4.1.0]heptene skeleton was confirmed by X-ray 



































Figure 2. X-ray crystallography of 34d 
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Unlike N-Ts tethered enynes, oxygen-tethered 1,6-enynes were 
not good substrates.19 A similar observation was made in the Ir-
catalyzed cycloisomerization of 1,6-enynes. When O-tethered 
enynes were reacted in the presence of Pd(MeCN)2Cl2 with P(OPh)3 
(1: 4), full conversion was observed, but too many spots were 
observed in the tlc plate. Thus, the same reaction was conducted in 
the presence of Pd(PPh3)4 and maleic imide. However, the expected 
reaction products were cleanly isolated in relatively low yields 
(entries 39 and 40: 37% and 20% yield, respectively). We next 
wanted to use a reaction of enynes with a carbon tether to 
investigate whether this palladium-catalyzed cycloisomerization was 
effective or not. Unfortunately, no reaction was observed. Thus, the 
formation of cyclopropanes takes place only with heteratom-


















Table 2. Scope of Pd-catalyzed cycloisomerization.[a]  
 






































19 (R = cyclopropyl)  
20 (R = Me) 
























22 (R = Me)  
23 (R = cyclopropyl)  































26 (R = C6H5) 
































































28 (R = Me) 
29 (R = Et) 
30 (R = n-Pr) 
31 (R = t-Bu) 
32 (R = cyclopropyl) 
33 (R = cyclobutyl) 

































35 (R = C6H5) 























37 (R = MeOC6H4) 

























39 (R = Et) 















[a] Reaction conditions: 10 mol% Pd(MeCN)2Cl2/ 40 mol% P(OPh)3, toluene, 130
oC, 24 h 
(or 10 mol% of Pd(PPh3)4/40 mol% maleimide, dichloroethane, 70
oC, 7 h). [b] Yield of the 
isolated product. [c] 3b, 5b, and 7b were isolated in 16%, 8%, and 8% yields, respectively. 
[d] 15 mol% Pd(MeCN)2Cl2 was used. [e] Compound 10 was recovered in 30%. [f] 
Compound 12 was recovered in 18 %. [g] No reaction was observed. [h] Reactions were 
carried out at 90oC [i] Reactions were carried out at 80oC. Compounds 24 and 25 were 



























Initially, we envisioned that mechanisms for the cycloisomerization 
reactions of enynes catalyzed by Pt(II) and Pd(II) might be different 
to each other. However, other previous studies proposed that the 
cyclization of enynes (intramolecular reaction of enol ethers with 
alkynes) with PtII, PdII, AuIII, and CuI (in methanol) take place by a 
common mechanism.21 In the methoxy- or hydroxycyclization 
reactions of enynes, palladium-catalyzed reactions showed 
selectivities similar to those observed with PtII complexes.22 
Furthermore, our experimental results also suggested that the 
palladium-catalyzed reaction is closely related to the electrophilic 
metal-catalyzed reactions. Thus, a mechanism similar to that 
proposed for PtII-catalyzed reactions23 can also be postulated for 
the process catalyzed by palladium. Complexation of Pd(II) renders 
the alkyne susceptible to nucleophilic attack by the tethered alkene. 
The nucleophilic attack can occur by 5-exo-dig or 6-endo-dig 
pathways to give cyclopropylcarbenes I and II, respectively. 
Cyclopropyl palladium complexes have been proposed by Trost24 
and Murai25 as intermediates for the reaction of some enynes which 
give cyclopropane derivatives. The intermediates I and II stabilize 
along different pathways. The preference for either of these 
processes may ultimately depend on which one gains more 
stabilization via the heteroatom in the tether. It is well-known2d,26 
that the electron-deficient palladium catalysts are effective in the 
enyne methathesis reactions In this case, metallacyclopentene 
derivatives (III) are proposed as the key intermediates of a 
Pd(II)/Pd(IV) manifold.27 However, a metallacyclopetene-
28 
 
metallacyclopropane rearrangement takes place during the Pd(II)-
catalyzed cycloisomerization reactions of vinyl-substituted enynes24 
and of allylpropargy ether.28 An Alder-ene-type reaction may take 






 In conclusion, we have demonstrated that palladium-catalyzed 
reactions of nitrogen- and oxygen-bridged 1,6-enynes that affords 
3-aza- and 3-oxabicyclo[4.1.0]heptenes in reasonable to high 
yields and 1,6-enynes bearing a cyclopropyl moiety at the alkene 
affords bicyclic or monocyclic trienes as products depending on the 
presence or absence of a leaving group. The bicyclic or monocyclic 
trienes can form a class of important building blocks because they 
possess three double bonds that may be used for further 
derivatization. And current efforts are directed at gaining a deeper 
understanding of some of the fundamental principles dictating the 
reactivity of the substrates, as well as extending their utility by 
expanding the substrate scope. Further experiments have to be 
carried out to corroborate the proposed mechanism. A report on the 
full scope and limitations of the new cycloisomerization process will 
be available in due time. We envision that the reaction developed in 
this study will be easily accessible to many synthetic chemists and 





General remarks. All solvents were dried and distilled according to 
standard methods before use. Toluene, Dioxane were distilled from 
sodium. Pd2(dba)3, Pd(PPh3)4, Pd(OAc)2, Ni(acac)2, and Ni(OAc)2 
were purchased from Strem Chemical Co. Pd(MeCN)2Cl2 was 
prepared according to the literaure.30 Reactions were carried out in a 
microwave tube equipped with a stirring bar and sealed with a 
rubber septum, unless otherwise indicated. Elevated temperatures 
were maintained in thermostat-controlled oil baths. Reactions were 
monitored by thin-layer chromatography (TLC) carried out on 0.25 
mm E. Merck silica gel plates (60F-254) using UV light as a 
visualizing agent and acidic p-anisaldehyde, and heat as a 
developing agent. Flash chromatography was carried out on Merck 
60 silica gel (230 – 400 mesh). 1H and 13C NMR spectra were 
recorded with Bruker (300 MHz) spectrometer, Varian spectrometer 
(400 MHz), and Varian spectrometer (500 MHz). 1H NMR spectra 
were referenced to residual TMS (0.0 ppm) and reported as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, b = broad, m = multiplet). Chemical shifts of the 13C NMR 
spectra were measured relative to CDCl3 (77.00 ppm). Mass data 
were obtained from the Korea Basic Science Institute (Daegu) on a 
Jeol JMS 700 high resolution mass spectrometer. Single crystal data 
for 17d and 34d were collected on an Enraf-Nonius CCD single 
crystal X-ray diffractometer at room temperature using graphite-
monochromated Mo Kα radiation (λ = 0.71073Å). Structures were 
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solved by direct methods using SHELXS-97 and refined by full-
matrix least-squares with SHELXL-97. Compounds 2 - 6,31 7,32 11 
– 12,33 13,34 20 – 21,35 22,36 23,31 2c – 6c,31 5b,37 7c,32 11d – 12d,33 
13c,34 20c – 21c,35 22c,36 and 23c31 were known. 
 







To a solution of N-(3-cyclopropylprop-2-ynyl)-4-
methylbenzenesulfonamide (0.872 g, 3.5 mmol) and PPh3 (0.92 g, 
3.5 mmol) in THF (30 mL) was added DIAD (diisopropyl 
azodicarboxylate) (0.68 mL, 3.5 mmol) at room temperature. To the 
above solution, (E)-3-(4-methoxyphenyl)prop-2-en-1-ol was 
added. The reaction mixture was stirred for 24 h at room 
temperature. After the solvent was removed by a rotary evaporator, 
the residue was purified by flash column chromatography eluting 
with Hexane/EtOAc(15:1). 
 
General procedure for palladium-catalyzed reactions (a, b,c ): To a 
flame-dried 10 mL Schlenk flask capped with a rubber septum, 











added under N2 flow. Compound 1 (0.3 mmol) was added to the flask 
under N2. The mixture was heated at 90 °C and the progress of the 
reaction was monitored by TLC. The mixture was cooled to room 
temperature, filtered, and the solvent was evaporated under reduced 
pressure. The product was purified by flash chromatography on a 
silica gel column (n-hexane–ethyl acetate, 10:1). 
General procedure for palladium-catalyzed reactions (d,e,f): 10 
mol % Pd(MeCN)2Cl2, 40 mol % Triphenyl phosphite and toluene (2 
mL) were added to a microwave tube equipped with a stirring bar 
and capped with a rubber septum. After 5 min, The solution was 
stirred for 5 min. A substrate (0.3 mmol) and toluene (1 mL) were 
added to the tube reactor and the resulting solution was heated. The 
resulting mixture was reacted until the substrate was completely 
consumed (reaction monitored by TLC). The product was purified 













Characterization of New compounds 
1: 1H NMR (300 MHz, CDCl3) δ 7.38 (d, J = 8.2 Hz, 2 H), 6.98 (d, J 
= 8.1 Hz, 2 H), 5.08 – 4.97 (m, 1 H), 4.88 (dd, J = 8.6, 15.2 Hz, 
1H), 4.06 (d, J = 9.6 Hz, 2 H), 3.82 – 3.71 (m, 6 H), 3.39 (d, J = 
6.6 Hz, 2 H), 2.10 (s, 3 H), 1.00 (t, J = 7.0 Hz, 7 H), 0.37 – 0.33 (m, 
2 H), 0.02 – 0.00 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.7, 
140.9, 136.2, 129.6, 127.9, 120.5, 80.9, 79.5, 64.2, 64.1, 54.98, 
54.92, 48.5, 35.8, 21.6, 16.3, 16.2, 13.5, 7.0 ppm. HRMS (FAB) m/z: 
[M + H]+ Calcd for C21H30NO6SP1 : 456.1610, found: 456.1613.  
2: 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.2 Hz, 2 H), 7.29 (d, J 
= 8.1 Hz, 2H), 5.43 – 5.33 (m, 1H), 5.20 (dd, J = 8.6, 15.3 Hz, 1 H), 
4.38 (s, 2 H), 4.10 (s, 2 H), 3.72 (d, J = 6.7 Hz, 2 H), 2.43 (s, 3 H), 
2.05 (s, 3 H), 1.41 – 1.33 (m, 1H), 0.74 – 0.67 (m, 2H), 0.37 – 0.33 
(m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 170.2, 143.6, 141.0, 
136.2, 129.5, 128.0, 120.6, 79.9, 79.5, 52.0, 48.6, 35.9, 21.7, 20.8, 
13.5, 7.0 ppm. HRMS (FAB) m/z: [M + H]+ Calcd for C19H23NO4S : 
362.1426, found: 362.1425. 
3 :1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.2 Hz, 2 H), 7.30 (d, J 
= 8.1 Hz, 2 H), 5.43 – 5.33 (m, 1 H), 5.20 (dd, J = 8.6, 15.3 Hz, 1 
H),. 4.44 (s, 2 H), 4.11 (s, 2 H), 3.80 (s, 3 H), 3.71 (d, J = 6.8 Hz, 
2 H), 2.42 (s, 3 H), 1.41 – 1.32 (m, 1 H), 0.73 – 0.67 (m, 2 H), 0.37 
– 0.32 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 155.2, 143.7, 
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141.0, 136.1, 129.6, 128.0, 120.5, 80.7, 78.9, 55.4, 55.3, 48.6, 35.8, 
21.7, 13.6, 7.0 ppm. HRMS (FAB) m/z: [M + H]+ Calcd for 
C19H23NO5S : 378.1375, found: 378.1378 
4: 1H NMR (300 MHz, CDCl3) δ 6.94 (s, 2 H), 5.37 – 5.28 (m, 1 H), 
5.22 – 5.15 (dd, J = 8.5, 15.2 Hz, 1 H), 4.63 (d, J = 9.7 Hz, 2 H), 
4.17 - 4.08 (m, 4 H), 4.03 (s, 2 H), 3.73 (d, J = 6.6 Hz, 2 H), 
2.59(s, 6 H), 2.30 (s, 3 H), 1.34 (t, J = 6.9 Hz, 7 H), 0.70 – 0.68 (m, 
2 H), 0.34 – 0.33 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 142.9, 
141.1, 140.5, 132.6, 132.2, 120.7, 82.0, 78.8, 64.3, 64.2, 55.37, 
55.30, 47.7, 34.5, 23.0, 21.1, 16.3, 16.2, 13.6, 7.0 ppm. HRMS 
(FAB) m/z: [M + H]+ Calcd for C23H34NO6SP1: 484.1923, found: 
484.1920. 
5: 1H NMR (500 MHz, CDCl3) δ 8.41 (s, 1 H), 7.97 – 7.95 (m, 2 H), 
7.91 (d, J = 8.0 Hz, 1 H), 7.82 (dd, J = 1.7, 8.7 Hz, 1 H), 7.65 – 
7.58 (m, 2 H), 5.41 – 5.35 (m, 1 H), 5.21 (dd, J = 8.8, 15.2 Hz, 1 H), 
4.188- 4.186 (d, J = 1.0 Hz, 3 H), 4.16 (d, J = 1.6 Hz, 1 H), 4.05 -
3.99 (m, 4 H), 3.79 (d, J = 6.8 Hz, 2 H), 1.36 – 1.32 (m, 1 H), 1.28 
(dt, J = 1.0, 7.1 Hz, 6 H), 0.70 -0.66 (m, 2H), 0.33 – 0.30 (m, 2 H) 
ppm. 13C NMR (75 MHz, CDCl3) δ 141.1, 136.1, 135.0, 132.2, 129.4, 
129.3, 129.2, 129.0, 128.0, 127.6, 127.6, 123.2, 120.5, 80.8, 79.7, 
64.2, 64.1, 54.8, 54.7, 48.7, 35.9, 16.2, 13.5, 7.0 ppm. HRMS (FAB) 
m/z: [M + H]+ Calcd for C24H30NO6SP1 : 492.1610, found: 492.1612. 
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6: 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.2 Hz, 2 H), 7.29 (d, J 
= 7.8 Hz, 2 H), 5.50 (d, J = 7.2 Hz, 1 H), 5.16 (dd, J = 8.7, 15.3 Hz, 
1 H), 4.92 (d, J = 7.1 Hz, 1 H), 4.46 (dd,  J = 1.6, 9.4 Hz, 2 H), 
4.11 (d, J = 7.2 Hz, 4 H), 3.86 (dd, J = 5.1, 15.9 Hz, 1 H), 3.66 (dd, 
J = 7.4, 15.9 Hz, 1 H), 2.42 (s, 3 H), 1.43 (d, J = 7.1 Hz, 3 H), 1.33 
(t, J = 7.0 Hz, 7 H), 0.70 - 0.67 (m, 2 H), 0.36 - 0.31 (m, 2 H) 
ppm. 13C NMR (75 MHz, CDCl3) δ143.5, 138.0, 136.8, 129.6, 127.8, 
124.5, 85.6, 79.2, 64.3, 64.2, 55.1, 55.0, 47.0, 46.2, 22.5, 21.7, 16.3, 
16.2, 13.5, 6.7 ppm. HRMS (FAB) m/z: [M + H]+ Calcd for 
C22H32NO6SP1 : 470.1766, found: 470.1768. 
7 :1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.1 Hz, 2 H), 7.29 (d, J 
= 8.1 Hz, 2 H), 5.57 – 5.47 (m, 1 H), 5.16 (dd, J = 8.5, 15.3 Hz, 1 
H), 4.65 (t, J = 7.7 Hz, 1 H), 4.46 (d, J = 9.3 Hz, 2 H), 4.14 – 4.05 
(m, 4 H), 3.86 – 3.79 (m, 1 H), 3.61 (dd, J = 7.7, 15.8 Hz, 1 H), 
2.43 (s, 3 H), 1.80 – 1.70 (m, 2 H), 1.35 – 1. 31 (m, 7 H), 1.00 (t, J 
= 7.3 Hz, 3 H), 0.68 (dd, J = 3.6, 9.8 Hz, 2 H), 0.34 – 0. 30 (m, 2 
H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.2, 137.7, 136.6, 129.3, 
127.6, 124.1, 84.6, 77.4, 64.0, 63.9, 54.9, 52.3, 47.0, 28.7, 21.5, 
16.1, 16.0, 13.2, 10.7, 6.5, 6.4 ppm. HRMS (FAB) m/z: [M + H]+ 
Calcd for C23H34NO6SP1 : 484.1923, found: 484.1924. 
8 :1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 8.2 Hz, 2 H), 7.27 (d, J 
= 7.7 Hz, 2 H), 5.67 (dd, J = 6.4, 15.1 Hz, 1 H), 5.19 (dd, J = 8.7, 
15.3 Hz, 1 H), 4.54 (d, J = 9.6 Hz, 2 H), 4.11 (m, 6 H), 2.41 (s, 3 
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H), 1.66 (s, 6 H), 1.41 – 1.25 (m, 7 H), 0.73 – 0.67 (m, 2 H), 0.37 – 
0.35 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 142.7, 139.8, 137.7, 
129.2, 127.2, 125.3, 90.1, 77.6, 64.0, 63.9, 56.1, 55.1, 55.0, 49.5, 
30.4, 21.4, 16.1, 16.0, 13.3, 6.5 ppm. HRMS (FAB) m/z: [M + H]+ 
Calcd for C23H34NO6SP1 : 294.1164, found: 294.1161. 
9 :1H NMR (300 MHz, CDCl3) δ 7.69 (d, J = 7.9 Hz, 2 H), 7.31 (d, J 
= 7.7 Hz, 2 H), 5.34 – 5.24 (m, 1 H), 5.10 (dd, J = 8.6, 15.1 Hz, 1 
H), 4.62 (d, J = 9.2 Hz, 2 H), 4.16 – 4.11 (m, 4 H), 3.76 (d, J = 6.4 
Hz, 2 H), 3.25 (t, J = 7.3 Hz, 2 H), 2.51 (s, 2 H), 2.47 (s, 3 H), 1.35 
(t, J = 6.9 Hz, 7 H), 0.70 (d, J = 6.3 Hz, 2 H), 0.32 (d, J = 3.0 Hz, 2 
H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.5, 140.1, 137.1, 129.9, 
127.4, 121.6, 85.2, 76.2, 64.29, 64.21, 55.6, 50.7, 45.6, 21.7, 20.0, 
16.3, 16.2, 13.5, 7.0 ppm. HRMS (FAB) m/z: [M + H]+ Calcd for 
C22H32NO6SP1 : 470.1766, found: 470.1768. 
10 :1H NMR (300 MHz, CDCl3) δ 5.30 - 5.20 (m, 1 H), 5.14 - 5.04 
(m, 1 H), 4.61 (d, J = 9.7 Hz, 2 H), 4.19 - 4.07 (m, 4 H), 3.72 (s, 6 
H), 2.84 (s, 2 H), 2.68 (d, J = 7.3 Hz, 2 H), 1.36 - 1.31 (m, 6 H), 
1.26 - 1.21 (m, 1 H), 0.69 - 0.63 (m, 2 H), 0.31 - 0.27 (m, 2 H) 
ppm. 13C NMR (75 MHz, CDCl3) δ 170.4, 140.0, 120.2, 83.0, 77.4, 
64.2, 64.1, 57.3, 55.6, 52.9, 35.5, 23.1, 16.3, 16.2, 13.8, 6.8 ppm. 
HRMS (FAB) m/z: [M + H]+ Calcd for C19H29O8P1 : 417.1678, found: 
417.1680. 
11 :1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 7.8 Hz, 2 H), 7.29 (d, 
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J = 8.3 Hz, 2 H,) 5.39 (dd, J = 7.2, 14.6 Hz, 1 H), 5.20 (dd, J = 8.7, 
15.2 Hz, 1 H), 4.12 (s, 2 H), 3.83 (s, 2 H), 3.74 (d, J = 6.6 Hz, 2 H), 
3.19 (s, 3 H), 2.42 (s, 3 H), 1.38 - 1.31 (m, 1 H), 0.71 (d, J = 7.1 
Hz, 2 H), 0.34 (d, J = 3.7 Hz, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 
143.5, 140.8, 136.4, 129.9, 129.6, 128.0, 120.8, 81.3, 79.6, 59.8, 
57.6, 48.6, 35.9, 21.7, 13.6, 7.1 ppm. HRMS (FAB) m/z: [M + H]+ 
Calcd for C18H23NO3S : 334.1477, found: 334.1476. 
12 :1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.1 Hz, 2 H), 7.37 – 
7.29 (m, 3 H), 7.27 – 7.21 (m, 4 H), 5.45 – 5.35 (m, 1 H), 5.24 – 
5.16 (dd, J = 8.7, 15.2 Hz, 1 H), 4.38 (s, 2 H), 4.14 (s, 2 H), 3.91 
(s, 2 H), 3.75 (d, J = 6.7 Hz, 2 H), 2.33 (s, 3 H), 1.40 – 1.32 (m, 1 
H), 0.72 – 0.66 (m, 2 H), 0.35 – 0.30 (m, 2 H) ppm. 13C NMR (75 
MHz, CDCl3) δ 143.5, 140.8, 137.4, 136.4, 129.6, 128.1, 128.0, 
127.9, 120.8, 81.4, 79.6, 71.5, 57.2, 48.6, 36.0, 21.6, 13.6, 7.1 ppm. 
HRMS (FAB) m/z: [M + H]+ Calcd for C24H27NO3S : 410.1790, 
found: 410.1794. 
13 :1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 8.1 Hz, 2 H), 7.31 - 
7.24 (m, 7 H), 6.56 (d, J = 15.8 Hz, 1 H), 6.13 - 6.03 (m, 1 H), 
4.17 (s, 2 H), 3.98 (d, J = 6.7 Hz, 2 H), 3.85 (s, 2 H), 3.20 (s, 3 H), 
2.42 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.7, 136.3, 135.0, 
129.7, 128.8, 128.3, 128.0, 126.7, 123.2, 81.7, 79.4, 59.8, 57.6, 
49.0, 36.4, 21.7 ppm. HRMS (FAB) m/z: [M + H]+ Calcd for 
C21H23NO3S : 370.1477, found: 370.1480. 
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14: 1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 8.2 Hz, 2 H), 7.29 (d, 
J = 8.1 Hz, 2 H), 5.78 – 5.64 (m, 1 H), 5.41 – 5.32 (m, 1 H), 4.12 (s, 
2 H), 3.83 (s, 2 H), 3.75 (d, J = 6.7 Hz, 2 H), 3.19 (s, 3 H), 2.42 (s, 
3 H), 1.69 (d, J = 6.2 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3) δ 
143.5, 136.4, 131.7, 129.5, 127.9, 124.8, 81.3, 79.5, 59.7, 48.6, 
35.9, 21.7, 17.9 HRMS (FAB) m/z: [M + H]+ Calcd for C16H21NO3S : 
308.1320, found: 308.1318. 
1-D: 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.1 Hz, 2 H), 7.30 (d, 
J = 8.0 Hz, 2 H), 5.19 (d, J = 8.6 Hz, 1 H), 4.39 (d, J = 9.4 Hz, 2 H), 
4.15 – 4.05 (m, 6 H), 3.71 (s, 2 H), 2.43 (s, 3 H), 1.34 (t, J = 7.0 
Hz, 7 H), 0.74 - 0.68 (m, 2 H) 0.37 - 0.32 (m, 2 H) ppm. 13C NMR 
(75 MHz, CDCl3) δ 143.7, 140.9, 136.2, 129.6, 127.9, 120.6, 80.9, 
79.6, 64.3, 64.2, 55.0, 54.9, 48.6, 35.8, 21.7, 16.3, 16.2, 13.5, 7.0 
ppm. HRMS (FAB) m/z: [M + H]+ Calcd for C21H29D1NO6SP1 : 
457.1672, found: 457.1674. 
15: 1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 7.8 Hz, 2 H), 7.30 (d, 
J = 7.8 Hz, 2 H), 4.75 (d, J = 9.4 Hz, 1 H), 4.33 (d, J = 9.1 Hz, 2 H), 
4.11 - 4.04 (m, 6 H), 3.62 (s, 2 H), 2.43 (s, 3 H), 1.75 (s, 3 H), 
1.50 - 1.47 (m, 1 H), 1.33 (t, J = 6.9 Hz, 6 H), 0.74 (d, J = 7.3 Hz, 
2 H), 0.30 (d, J = 3.6 Hz, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 
143.7, 136.2, 135.4, 129.5, 128.0, 127.2, 80.8, 79.6, 64.2, 64.2, 
54.9, 54.5, 35.5, 21.7, 16.3, 16.2, 14.4, 10.3, 7.1 ppm HRMS (FAB) 
m/z: [M + H]+ Calcd for C22H32NO6SP1 : 470.1766, found: 470.1768. 
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16: H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 7.8 Hz, 2 H), 7.29 (d, J 
= 8.3 Hz, 2 H,) 5.39 (dd, J = 7.2, 14.6 Hz, 1 H), 5.20 (dd, J = 8.7, 
15.2 Hz, 1 H), 4.12 (s, 2 H), 3.83 (s, 2 H), 3.74 (d, J = 6.6 Hz, 2 H), 
3.19 (s, 3 H), 2.42 (s, 3 H), 1.38 - 1.31 (m, 1 H), 0.71 (d, J = 7.1 
Hz, 2 H), 0.34 (d, J = 3.7 Hz, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 
143.5, 140.8, 136.4, 129.9, 129.6, 128.0, 120.8, 81.3, 79.6, 59.8, 
57.6, 48.6, 35.9, 21.7, 13.6, 7.1 ppm. HRMS (FAB) Calcd for 
[C18H23NO3S] : 334.1477, found: 334.1476. 
17 :1H NMR (300 MHz, CDCl3) δ. 7.73 (d, J = 8.1 Hz, 2 H), 7.27 (d, 
J = 8.4 Hz, 2 H), 5.43 – 5.36 (m, 1 H), 5.20 (dd, J = 8.6, 15.3Hz, 1 
H), 4.03 (s, 2 H), 3.72 (d, J = 6.7 Hz, 2 H), 2.41 (s, 3 H), 1.91 (q, J 
= 7.4 Hz, 2 H), 1.36 (dt, J = 3.7, 8.2 Hz, 1 H), 0.90 (t, J = 7.4 Hz, 3 
H), 0.71 – 0.67 (m, 2 H), 0.35 – 0.32 (m, 2 H) ppm. 13C NMR (75 
MHz, CDCl3) δ 143.2, 140.4, 136.5, 129.4, 128.0, 121.0, 87.4, 72.0, 
48.2, 36.1, 21.6, 13.7, 13.5, 12.2, 6.9 ppm.  
18 :1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8 2 Hz, 2 H), 7.28 (d, 
J = 8.1 Hz, 2 H), 5.44 – 5.34 (m, 1 H) 5.21 (dd, J = 8.6, 15.3 Hz, 1 
H), 4.08 (d, J = 2.3 Hz, 2 H), 3.75 (d, J = 6.7 Hz, 2 H) 2.42 (s, 3 H),   
1.98 (t, J = 2.3, 1 H) 1.41 – 1.31 (m, 1 H), 0.74 – 0.68 (m, 2 H), 
0.37 – 0.32 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.6, 141.0, 




19: 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.1 Hz, 2 H), 7.28 (d, 
J = 8.0 Hz, 2 H). 5.43 – 5.34 (m, 1 H), 5.19 (dd, J = 8.8, 15.0 Hz, 1 
H), 4.00 (s, 2 H), 3.71 (d, J = 6.5 Hz, 2 H), 2.42 (s, 3 H), 1.53 (s, 3 
H), 1.39 – 1.19 (m, 1 H), 0.71 – 0.68 (m, 2 H), 0.35 – 0.33 (m, 2 H) 
ppm 13C NMR (75 MHz, CDCl3) δ 143.7, 135.0, 129.9,127.2, 119.9, 
118.3, 40.6, 32.5, 25.3, 21.7, 17.3, 16.4, 13.1 ppm.  
20: 1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 8.0 Hz, 2 H), 7.28 (d, 
J = 8.1 Hz, 2 H), 5.72 – 5.64 (m ,1 H), 5.40 – 5.29 (m, 1 H), 4.00 (d, 
J = 2.0 Hz, 2 H), 3.72 (d, J = 6.7 Hz, 2 H), 2.42 (s, 3 H), 1.68 (d, 3 
H), 1.54 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.0, 136.3, 
131.1, 129.4, 129.1, 127.8, 124.8, 81.3, 71.8, 48.2, 35.9, 21.4, 17.6, 
3.2 ppm.  
21: 1H NMR (300 MHz, CDCl3) δ 7.78 (d, J = 7.8 Hz, 2 H), 7.32 – 
7.29 (m, 7 H), 6.55 (d, J = 15.8 Hz, 1 H), 6.13 – 6.03 (m, 1 H), 4.05 
(s, 2 H), 3.96 (d, J = 6.7 Hz, 2 H), 2.42 (s, 3 H), 1.58 (s, 3 H) ppm. 
13C NMR (75 MHz, CDCl3) δ 143.4, 136.4, 134.6, 129.4, 128.8, 
128.1, 126.7, 123.5, 81.8, 71.9, 48.7 36.6, 21.7, 3.5 ppm.  
22: 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.0 Hz, 2 H), 7.29 (d, 
J = 7.9 Hz, 2 H), 5.74 – 5.62 (m, 1 H), 5.40 – 5.31 (m, 1 H), 4.00 (s, 
2 H), 3.71 (d, J = 6.6 Hz, 2 H), 2.43 (s, 3 H), 1.68 (d, J = 6.0 Hz, 3 
H), 0.95 – 0.94 (d, J = 4.8 Hz, 1 H), 0.63 – 0.59 (m, 2 H), 0.32 – 
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0.29 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.3, 1316.4, 
131.3, 129.4, 127.9, 124.9, 89.2, 67.8, 48.3, 36.1, 21.6, 17.8, 7.9, - 
0.7 ppm.  
23: 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.2 Hz, 2 H), 7.29 (d, 
J = 8.5 Hz, 2 H), 5.44 – 5.35 (m, 1 H), 5.19 (dd, J = 8.6, 15.2 Hz, 1 
H), 4.01 (d, J = 1.6 Hz, 2 H), 3.71 (d, J = 6.7 Hz, 2 H), 2.43 (s, 3 
H), 1.43 – 1.25 (m, 1 H), 0.97 – 0.91 (m, 1 H), 0.72 – 0.67 (td, J = 
4.4, 6.1 Hz, 2 H), 0.61 (td, J = 4.1, 6.4 Hz, 2 H), 0.37 -0.27 (m, 4 
H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.3, 140.4, 136.5, 129.5, 
128.0, 121.0, 89.2, 68.0, 48.3, 36.2, 21.7, 13.6, 8.0, 7.0, -0.6 ppm. 
HRMS (FAB) calc. for [C19H23NO2S]:329.1149, found:329.1152 
24: 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 8.2 Hz, 2 H), 7.32 (dd, 
J = 3.4, 7.3 Hz, 7 H), 6.55 (d, J = 15.8 Hz, 1 H), 6.09 (td, J = 6.8, 
15.7 Hz, 1 H), 4.06 (d, J = 1.5 Hz, 2 H), 3.96 (d, J = 6.7 Hz, 2 H), 
2.44 (s, 3 H), 1.01 - 0.95 (m, 1 H), 0.66 – 0.60 (m, 2 H), 0.37- 
0.31 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.3. 136.2(2). 
136.2(1), 134.4, 129.3, 128.5, 127.9, 127.7, 126.4, 123.2, 89.3, 
77.3, 77.0, 76.7, 67.7, 48.5, 36.5, 21.5, 7.8, -0.8  
25: 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.3 Hz, 2 H), 7.28 (d, 
J = 6.5 Hz, 2 H), 5.76 -5.73 (m, 1 H), 5.47 -5.30 (m, 1 H), 5.24 – 
5.16 (dd, J = 8.7, 15.2 Hz, 1 H), 4.17 (s, 2 H), 3.73 (d, J = 6.7 Hz, 
2 H), 2.40 (s, 3 H), 2.00(8) – 2.00(3) (m, 2 H), 1.79 – 1.85 (m, 2 
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H), 1.53 – 1.51 (m, 2 H), 1.37 – 1.28 (m, 1 H), 0.73 – 0.66 (m, 2 H), 
0.37 – 0.27 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.3, 140.6, 
136.4, 135.1, 129.5, 128.0, 120.9, 120.0, 87.5, 79.2, 48.4, 36.5, 
29.1, 25.7, 22.3,21.6, 21.5, 13.5, 7.0 ppm. HRMS (EI) calc. for 
[C22H27NO2S]:369.1792, found: 369.1802 
26: 1H NMR (300 MHz, CDCl3) δ 1.54-1.61 (m, 4 H), 1.82 (br s, 2 
H), 2.02 (br s, 2 H), 2.41 (s, 3 H), 3.98 (d, J = 6.8 Hz, 2 H), 4.22 (s, 
2 H), 5.79 (s, 1 H), 6.11 (dt, J = 15.7, 6.9 Hz, 1 H), 6.57 (d, J = 
15.8 Hz, 1 H), 7.24-7.33 (m, 7 H), 7.76 (d, J = 7.9 Hz, 2 H) ppm. 
13C NMR (75 MHz, CDCl3) δ 143.3, 136.2, 135.1, 134.6, 129.4, 
128.5, 127.9, 127.8, 126.5, 123.2, 119.7, 87.6, 78.8, 48.6, 36.8, 
28.9, 25.5, 22.1, 21.5, 21.3 ppm. 
27: 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 8.2 Hz, 2H), 7.28 (dd, 
J = 6.1, 7.9 Hz, 4 H), 6.84 (d, J = 8.6 Hz, 2 H), 6.51 (d, J = 15.8 Hz, 
1 H), 6.01 - 5.91 (m, 1 H), 5.78 (bs, 1 H), 4.22 (s, 2 H), 3.95 (d, J 
= .8 Hz, 2 H), 3.81 (s, 3 H), 2.42 (s, 3 H), 2.03 (bs, 2 H), 1.83 (bs, 
2 H), 1.57 – 1.54 (m, 4 H) ppm. 13C NMR (75 MHz, CDCl3) δ 159.7, 
143.4, 136.4, 135.3, 134.4, 129.6, 129.2, 128.0, 127.9, 121.0, 120.0, 
114.2, 87.7, 79.2, 55.5, 48.9, 36.9, 29.1, 25.7, 22.3, 21.7, 21.6 ppm. 
28: H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 8.1 Hz, 2 H), 7.28 (t, J 
= 8.9 Hz, 4 H), 6.84 (d, J = 8.6 Hz, 2 H), 6.49 (d, J = 15.8 Hz, 1 H), 
5.98 – 5.88 (m, 1 H), 4.04 (d, J = 2.1 Hz, 2 H), 3.93 (d, J = 6.7 Hz, 
2 H), 3.80 (s, 3 H), 2.43 (s, 3 H), 1.56 (s, 3 H) ppm. 13C NMR (75 
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MHz, CDCl3) δ 159.4, 143.2, 136.2, 134.0, 129.2, 129.0, 127.9, 
127.7, 120.9, 113.9, 81.5, 71.7, 55.3, 48.6, 36.3, 21.5, 3.3 ppm.  
29: 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 8.1 Hz, 2 H), 7.28 (t, J 
= 8.0 Hz, 4 H), 6.84 (d, J = 8.6 Hz, 2 H), 6.50 (d, J = 15. 8Hz, 1 H), 
5.99 – 5.89 (m, 1 H), 4.08 (s, 2 H), 3.94 (d, J = 6.7 Hz, 2 H), 3.80 
(s, 3 H), 2.42 (s, 3 H), 1.94 (dd, J = 7.4, 14.9 Hz, 2 H), 0.93 (t, J = 
7.5 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3) δ 159.4, 143.2, 136.3, 
124.0, 129.3, 129.0, 127.8, 127.7, 120.9, 114.0, 87.5, 71.9, 55.3, 
48.5, 36.3, 21.4, 13.5, 12.1 ppm. HRMS (EI) calc. for 
[C22H25NO3S]:383.1555, found: 383.1554 
30: 1H NMR (300 MHz, CDCl3 δ 7.76 (d, J = 8.2 Hz, 2 H), 7.29 – 
7.25 (m, 4 H), 6.84 (d, J = 8.7 Hz, 2 H)  6.50 (d, J = 15.8 Hz, 1 H), 
5.95 (td, J = 6.8, 15.7, 1 H), 4.09 (s, 2 H), 3.95 (d, J = 6 8 Hz, 2 H), 
3.79 (s, 3 H), 2.41 (s, 3 H), 1.91 (dd, J = 4.6, 9.4 Hz, 2 H), 1.35 – 
1.23 (m, 2 H), 0.85 – 0.81 (t, J = 7.3 Hz, 3 H) ppm. δ 159.6, 143.4, 
136.5, 134.2, 129.5, 129.2, 128.0, 127.9, 121.1, 114.1, 86.3, 72.8, 
55.5, 48.7, 36.5, 22.0, 21.6, 20.6, 13.6 ppm HRMS (EI) calc. for 
[C23H27NO3S]: 397.1712, found: 396.1628 
31: 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 8.1 Hz, 2 H), 7.31 – 
7.25 (m, 4 H), 6.85 (d, J = 8.6 Hz, 2 H), 6.51 (d, J = 15.8 Hz, 1 H), 
6.0 – 5.91 (m, 1 H), 4.10 (s, 2 H), 3.95 (d, J = 6.8 Hz, 2 H), 3.81 (s, 
3 H), 2.42 (s, 3 H), 1.00 (s, 9 H) ppm. 13C NMR (75 MHz, CDCl3) δ 
159.7, 143.4, 136.6, 134.4, 129.7, 129.3, 128.0, 127.9, 121.0, 114.2, 
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94.8, 71.1, 55.5, 48.7, 36.5, 30.9, 27.3, 21.7 ppm. HRMS (EI) calc. 
for [C24H29NO3S]: 411.1868, found: 411.1864 
32: 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 8.2 Hz, 2 H), 7.31 – 
7.26 (m, 5 H), 6.85 (d, J = 8.7 Hz, 2 H), 6.49 (d, J = 15.8 Hz, 1 H), 
5.94 (td, J = 6.8, 15.7 Hz 1 H), 4.05 (s, 2 H), 3.93 (d, J = 6.8 Hz, 2 
H), 3.81 (s, 3 H), 2.44 (s, 3 H), 1.00 - 0.97 (m, 1 H), 0.66 -0.59 
(m, 1 H), 0.36 – 0.31 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 
159.7, 143.5, 136.5, 134.2, 129.6, 129.2, 127.9, 121.2, 114.2, 89.5, 
68.0, 55.5, 48.8, 36.6, 21.7, 8.1, -0.6 ppm. HRMS (EI) calc. for 
[C23H25NO3S] : 395.1555, found: 394.1480 
33: 1H NMR (300 MHz, CDCl3) δ 7.77 (d, J = 7.9 Hz, 2 H), 7.27 (d, 
J = 8.4 Hz, 4 H), 6.86 (d, J = 8.3 Hz, 2 H), 6.50 (d, J = 15.7 Hz, 1 
H) 6.00 – 5.91 (m, 1 H), 4.11 (s, 2 H), 3.95 (d, J = 6.6 Hz, 2 H), 
3.81 (s, 3 H), 2.76 – 2.74 (m, 1 H), 2.43 (s, 3 H), 2.09 (d, J=7.7Hz, 
2 H), 1.85 – 1.74 (m, 4 H) ppm. 13C NMR (75 MHz, CDCl3) δ 159.7, 
143.5, 136.6, 134.3, 129.6, 129.3, 128.1, 128.0, 121.2, 114.2, 90.2, 
73.6, 55.5, 48.9, 36.7, 31.2, 29.8, 24.9, 21.8, 19.3 ppm. HRMS 
(FAB) [M + H]+calc. for [C24H27NO3S]:, 409.1712 found: 410.1791 
34: 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 7.9 Hz, 2 H), 7.19 (t, J 
= 6.6 Hz, 4 H), 6.94 (d, J = 8.5 Hz, 2 H), 6.73 (dd, J = 8.5, 21.7 Hz, 
4 H), 6.46 (d, J = 15.7 Hz, 1 H) 5.96 -5.87 (m, 1 H), 4.23 (s, 2 H), 
3.93 (d, J = 6.7 Hz, 2 H), 3.72 (s, 6 H), 2.28 (s, 3 H) ppm. 13C NMR 
(75 MHz, CDCl3) δ 159.7, 159.6, 143.5, 136.2, 134.4, 133.1, 129.6, 
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128.0, 127.9, 120.9, 114.1, 113.9, 85.7, 80.5, 55.4, 49.0, 36.9, 21.6 
ppm.  
35: 1H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 8.1 Hz, 2 H), 7.53 (d, 
J = 6.8 Hz, 2 H), 7.25 – 7.37 (m, 5 H), 5.56 (s, 1 H), 5.32 (s, 1 H), 
4.22 (s, 2 H), 3.93 (s, 2 H), 2.45 (s, 3 H), 0.89 – 0.95 (m, 1 H), 
0.57 – 0.63 (m, 2 H), 0.25 – 0.30 (m, 2 H) ppm. 13C NMR (75 MHz, 
CDCl3) δ 143.39, 141.45, 137.84, 135.82, 129.36, 128.44, 128.12, 
127.99, 126.43, 116.99, 89.73, 67.36, 49.93, 36.10, 21.55, 7.86, -
0.82 ppm. 
36: 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 8.2 Hz, 2 H), 7.54 (dd, 
J = 5.4, 8.7 Hz, 2 H), 7.33 (d, J = 8.1 Hz, 2 H), 7.04 (t, J = 8.7 Hz, 
2 H), 5.53 (s, 1 H), 5.31 (s, 1 H), 4.21 (s, 2 H), 3.92 (d, J = 1.5 Hz, 
2 H), 2.46 (s, 3 H), 0.90 – 0.96 (m, 1 H), 0.58 - 0.65 (m, 2 H), 
0.25 – 0.31 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.50, 
140.37, 135.63, 129.38, 128.22, 128.11, 127.95, 117.04, 115.43, 
115.14, 89.84, 67.11, 50.04, 36.03, 21.54, 7.86, -0.96 ppm. 
37: 1H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 8.2 Hz, 2 H), 7.48 – 
7.46 (m, 2 H), 7.29 (d, J = 8.2 Hz, 2 H), 6.86 (d, J = 8.9 Hz, 2 H), 
5.46 (s, 1 H), 5.20 (s, 1 H), 4.17 (s, 2 H), 3.89 (q, J = 2.1 Hz, 2 H), 
3.80 (s, 3 H), 2.42 (s, 3 H), 1.48 (t, J = 2.3 Hz, 3 H) ppm. 13C NMR 
(75 MHz, CDCl3) δ 159.5, 143.1, 140.7, 135.7, 130.1, 129.1, 128.0, 
127.5, 115.2, 113.7, 81.7, 71.3, 55.2, 50.1, 35.9, 21.4, 3.1 ppm.  
46 
 
38 :1H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 8.2 Hz, 2 H), 7.61 (q, 
J = 8.6 Hz, 4 H), 7.31 (d, J = 8.1 Hz, 2 H), 5.63 (s, 1 H), 5.43 (s, 1 
H), 4.24 (s, 2 H), 3.91 (d, J = 2.2 Hz, 2 H), 2.44 (s, 3 H), 1.51 (s, 3 
H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.4, 141.3, 140.7, 135.6, 
129.2, 128.0, 126.7, 125.3(9), 125.3(3), 119.0,82.1, 71.0, 
49.9 ,36.1, 21.4, 3.1 ppm.  
39 :H NMR (300 MHz, CDCl3) δ 7.33 (d, J = 8.6 Hz, 2 H), 6.85 (d, J 
= 8.6 Hz, 2 H), 6.57 (d, J = 15.9 Hz, 1 H), 6.15 (td, J = 6.3, 15.8 
Hz, 1 H), 4.19 – 4.16 (m, 4 H), 3.81 (s, 3 H), 2.28 – 2.17 (m, 2 H), 
1.16 (t, J = 7.5 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3) δ 159.3, 
132.7, 129.4, 127.7, 123.1, 113.9, 88.3, 75.2, 70.2, 57.5, 55.2, 13.8, 
12.4 ppm. HRMS (EI) calc. for [C15H18O2]: 230.1307, found: 
230.1411 
40 :1H NMR (300 MHz, CDCl3) δ 7.32 (d, J = 8.5 Hz, 2 H), 6.85 (d, 
J = 8.5 Hz, 2 H), 6.58 (d, J = 15.9 Hz, 1 H), 6.19 -6.10 (m, 1 H), 
4.19 (d, J = 6.6 Hz, 4 H), 3.81 (s, 3 H), 2.22 (t, J = 6.9 Hz, 2 H), 
1.58 – 1.51 (m, 2 H), 1.00 (t, J = 7.3 Hz, 3 H) ppm. 13C NMR (75 
MHz, CDCl3) δ 159.3, 132.7, 129.4, 127.7, 123.2, 113.9, 86.9, 76.1, 
57.5, 55.2, 22.0, 20.7, 13.5 ppm. HRMS (FAB) calc. for [C16H20O2]: 
244.1463, found: 244.1461 
1a: 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 8.1 Hz, 2 H), 7.33 (d, J 
= 8.0 Hz, 2 H), 6.02 (dd, J = 5.4, 11.1 Hz, 1 H), 5.67 (d, J = 11.0 
Hz, 1 H), 4.84 (s, 1 H), 4.73 (s, 1 H), 4.34 (d, J = 3.4 Hz, 2 H), 
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4.21 (d, J = 3.3 Hz, 2 H), 2.43 (s, 5 H), 2.31 (t, J = 7.3 Hz, 2 H) 
ppm. 13C NMR (75 MHz, CDCl3) δ 143.6, 142.6, 136.8, 134.0, 132.1, 
130.7, 129.9, 127.6, 121.9, 114.3, 58.8, 56.8, 34.0, 28.5, 21.6 ppm 
HRMS (EI) m/z: [M]+ Calcd for C17H19NO2S : 301.1137, found: 
301.1142. 
4a :1H NMR (300 MHz, CDCl3) δ 6.96 (s, 2 H), 6.06 (dd, J = 5.8, 
10.8 Hz, 1 H), 5.70 (d, J = 11.1 Hz, 1 H), 4.85 (s, 1 H), 4.73 (s, 1 
H), 4.35 (d, J = 3.4 Hz, 2 H), 4.19 (s, 2 H), 2.65 (s, 6 H), 2.49 - 
2.46 (m, 2 H), 2.38-2.36 (m, 2 H), 2.32 (d, J = 8.8 Hz, 3 H) ppm. 
13C NMR (75 MHz, CDCl3) δ 142.8, 142.7, 140.3, 136.8, 136.7, 
132.6, 132.5, 132.1, 130.7, 122.1, 114.3, 57.7, 55.6, 34.1, 28.6, 
23.1, 21.1 ppm. HRMS HRMS (FAB) m/z: [M + H]+ Calcd for 
C19H23NO2S : 330.1528, found: 330.1530. 
5a: 1H NMR (300 MHz, CDCl3) δ 8.43 (s, 1 H), 7.99 (d, J = 8.0 Hz, 
2 H), 7.93 – 7.84 (m, 2 H), 7.64 (s, 2 H), 6.04 - 5.99 (m, 1 H), 
5.66 (d, J = 11.1 Hz, 1 H), 4.83 (s, 1 H), 4.74 (s, 1 H), 4.43 (s, 2 
H), 4.29 (s, 2 H), 2.40 (d, J = 3.8 Hz, 2 H), 2.29 (s, 2 H) ppm. 13C 
NMR (75 MHz, CDCl3) δ 142.7, 137.0, 135.1, 134.2, 132.2, 130.7, 
129.6, 129.5, 128.9, 128.1, 127.7, 123.1, 121.9, 114.5, 59.0, 57.0, 
34.1, 28.6 ppm. HRMS (EI) m/z: [M]+ Calcd for C20H19NO2S : 
337.1136, found: 337.1139. 
6a: 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 7.3 Hz, 2 H), 7.27 (d, J 
= 7.3 Hz, 2 H), 5.97 – 5.94 (m, 1 H), 5.62 (d, J = 10.3 Hz, 1 H), 
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4.90 (s, 1 H), 4.81 (s, 1 H), 4.30 – 4.06 (m, 3 H), 2.40 – 2.32 (m, 7 
H), 1.47 (d, J = 6.1 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3) δ 
143.4, 142.3, 138.0, 136.6, 135.5, 129.8, 129.5, 127.4, 121.8, 115.2, 
64.9, 57.8, 34.3, 29.3, 22.3, 21.7 ppm. HRMS (FAB) m/z: [M + H]+ 
Calcd for C18H21NO2S : 316.1371, found: 316.1367. 
7a: 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J = 8.1 Hz, 2 H), 7.27 (d, J 
= 8.0 Hz, 2 H), 5.99 – 5.91 (m, 1 H), 5.64 – 5.59 (m, 1 H), 4.95 (s, 
1 H), 4.86 (d, J = 15.3 Hz, 1 H), 4.31 – 4.05 (m, 3 H), 2.41 – 2.34 
(m, 4 H), 2.20 – 2.14 (m, 1 H), 2.00 – 1.92 (m, 1 H)  1.85 – 1.76 
(m, 1 H), 1.64 (s, 1 H), 1.26 (s, 1 H), 0.88 – 0.79 (m, 3 H) ppm. 13C 
NMR (75 MHz, CDCl3) δ 143.4, 142.4, 136.4, 135.7, 130.6, 129.8, 
127.4, 121.6, 115.2, 69.9, 58.9, 34.1, 29.7, 27.1, 21.7, 8.3 ppm. 
HRMS (FAB) m/z: [M + H]+ Calcd for C19H23NO2S : 330.1528, 
found: 330.1532. 
8a: 1H NMR (300 MHz, CDCl3) δ 7.77 (d, J = 8.2 Hz, 2 H), 7.28 (d, J 
= 8.6 Hz, 2 H), 5.96 (d, J = 11.3 Hz, 1 H), 5.66 - 5.58 (m, 1 H), 
5.16 (s, 1 H), 4.95 (s, 1 H), 4.10 (s, 2 H), 2.41 (s, 7 H), 1.74 (s, 6 
H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.0, 142.3, 140.9, 138.4, 
136.5, 129.6, 127.8, 127.5, 121.3, 115.4, 75.5, 56.8, 36.0, 32.0, 
27.5, 21.6 ppm. HRMS (FAB) m/z: [M + H]+ Calcd for C19H23NO2S : 
330.1528, found: 330.1525. 
9a: 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J = 8.2 Hz, 2H), 7.32 (d, J 
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= 7.9 Hz, 2 H), 5.88 – 5.84 (m, 1 H), 5.41 (d, J = 12.1 Hz, 1 H), 
5.01 (s, 1 H), 4.86 (s, 1 H), 3.59 (s, 2 H), 3.15 (t, J = 5.7 Hz, 2 H), 
2.48 – 2.45 (m, 3 H), 2.42 (s, 4 H), 2.32 – 2.30 (m, 2 H) ppm. 13C 
NMR (75 MHz, CDCl3) δ 149.1, 143.8, 134.4, 132.4, 129.8, 128.0, 
127.9, 126.5, 125.8, 114.4, 50.0, 43.0, 35.3, 31.4, 29.3, 21.7 ppm. 
HRMS (FAB) m/z: [M + H]+ Calcd for C18H21NO2S : 316.1371, 
found: 316.1369. 
10a: 1H NMR (300 MHz, CDCl3) δ 5.96 (dd, J = 5.4, 11.1 Hz, 1 H), 
5.80 (d, J = 11.1 Hz, 1 H), 4.88 (s, 1 H), 4.82 (s, 1 H), 3.75 (s, 6 
H), 3.34 (s, 2 H), 3.24 (s, 2 H), 2.49 - 2.45 (m, 2 H), 2.37 - 2.33 
(m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 172.5, 144.7, 134.9, 
134.6, 133.0, 124.8, 113.6, 56.6, 52.9, 46.2, 43.4, 34.3, 28.6 ppm. 
HRMS (EI) m/z: [M]+ Calcd for C15H18O4 : 262.1205, found: 
262.1201. 
11b: 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.2 Hz, 2 H), 7.34 (d, 
J = 8.1 Hz, 2 H), 6.31 – 6.19 (m, 1 H), 6.09 (dd, J = 10.5, 15.0 Hz, 
1 H), 5.34 (dd, J = 8.5, 14.9 Hz, 2 H), 5.17 (d, J = 16.7 Hz, 1 H), 
5.06 (d, J = 9.7 Hz, 1 H), 4.01 (d, J = 14.6 Hz, 1 H), 3.82 (d, J = 
6.2 Hz, 2 H), 3.73 (d, J = 14.5 Hz, 1 H), 3.63 – 3.58 (m, 1 H), 3.29 
(s, 4 H), 2.78 (t, J = 9.2 Hz, 1 H), 2.45 (s, 3 H) ppm. 13C NMR (75 
MHz, CDCl3) δ 144.0, 141.5, 136.2, 134.4 ,132.6, 131.1, 129.9, 
128.0, 120.6, 117.5, 69.7, 58.5, 53.0, 49.6, 46.9, 21.7 ppm. HRMS 




12b: 1H NMR (300 MHz, CDCl3) δ 7.68 (d, J = 7.2 Hz, 2 H), 7.32 – 
7.26 (m, 7 H),  6.31 – 6.24 (m, 1 H), 6.12 – 6.03 (m, 1 H), 5.36 – 
5.31 (m, 2 H), 5.16 (d, J = 16.8 Hz, 1 H), 5.06 (d, J = 9.8 Hz, 1 H), 
4.45 (s, 2 H), 3.98 (d, J = 14.7 Hz, 1 H), 3.91 – 3.90 (m, 2 H), 3.69 
(d, J = 14.4 Hz, 1 H), 3.60 (t, J = 8.3 Hz, 1 H), 3.30 – 3.28 (m, 1 H), 
2.76 (t, J = 8.9 Hz 1 H), 2.44 (s, 3 H) ppm. 13C NMR (75 MHz, 
CDCl3) δ 144.0, 141.5, 138.0, 136.3, 134.4, 132.6, 131.1, 129.9, 
128.6, 128.0, 120.7, 117.5, 72.9, 67.4, 53.0, 49.7, 47.0, 21.7 ppm. 
HRMS (FAB) m/z: [M + H]+ Calcd for C24H27NO3S : 410.1790, 
found: 410.1788. 
13b: 1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 7.7 Hz, 2 H), 7.37 – 
7.26 (m, 5 H), 7.19 (d, J = 7.3 Hz, 2 H), 6.78 (s, 1 H), 6.04 (s, 1 H), 
4.28 (s, 2 H), 4.03 (s, 2 H), 3.99 (d, J = 6.3 Hz, 2 H), 3.35 (s, 3 H), 
2.43 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3) δ 144.1, 138.0, 136.2, 
133.9, 133.0, 130.1, 130.0, 128.9, 127.9, 121.6, 117.1, 69.9, 58.6, 
51.9, 49.9, 21.7ppm. HRMS (FAB) m/z: [M + H]+ Calcd for 
C21H23NO3S : 370.1477, found: 370.1474. 
14b: 1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 8.1 Hz, 2 H), 7.34 (d, 
J = 8.0 Hz, 2 H), 5.54 – 5.42 (m, 1 H), 5.35 (dd, J = 3.9, 6.3 Hz, 1 
H), 5.14 (s, 1 H), 5.09 (d, J = 7.4 Hz, 1 H), 4.02 – 3.89 (m, 2 H), 
3.82 (d, J = 6.5 Hz, 2 H), 3.75 – 3.70 (m, 1 H), 3.63 – 3.58 (m, 1 H), 
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3.28 (d, J = 3.6 Hz, 3 H), 2.79 (t, J = 9.2 Hz, 1 H), 2.45 (s, 3 H) 
ppm. 13C NMR (75 MHz, CDCl3) δ144.0, 141.3, 135.7, 132.6, 129.9, 
128.0, 120.5, 118.6, 69.7, 58.5, 52.8, 49.6, 48.0, 21.7 ppm. HRMS 
(FAB) m/z: [M + H]+ Calcd for C16H21NO3S : 308.1320, found: 
308.1317. 
15c: 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J = 7.4 Hz, 2 H), 7.33 (d, 
J = 7.9 Hz, 2 H), 6.44 (s, 1 H), 6.19 (td, J = 10.2, 17.0 Hz, 1 H), 
6.09 (dd, J = 11.3, 17.8 Hz, 1 H), 5.91 (dd, J = 10.3, 15.5 Hz, 1 H), 
5.53 (d, J = 15.6 Hz, 1 H), 5.15 – 5.07 (m, 2 H), 5.03 (d, J = 10.1 
Hz, 1 H), 4.93 (d, J = 11.3 Hz, 1 H), 3.37 (dd, J = 1.0, 10.3 Hz, 1 
H), 3.30 (d, J = 10.3 Hz, 1 H), 2.44 (s, 3 H), 1.24 (s, 3 H) ppm. 13C 
NMR (125 MHz, CDCl3) δ 144.2, 138.7, 136.6, 130.5, 130.2, 130.0, 
128.6, 128.1, 128.1, 127.8, 117.2, 114.1, 62.1, 49.0, 23.4, 21.8 ppm. 
HRMS (FAB) m/z: [M + H]+ Calcd for C18H21NO2S : 316.1371, 
found: 316,1373.  
16d: 1H NMR (300 MHz, CDCl3) δ 7.66 (d, J = 7.9 Hz, 2 H), 7.34 (d, 
J = 7.9 Hz, 2 H), 6.38 (d, J = 8.1 Hz, 1 H), 5.52 (d, J = 8.1 Hz, 1 H), 
3.94 (d, J = 11.8 Hz, 1 H), 3.54 (d, J = 10.1 Hz, 1 H), 3.38 (d, J = 
16.1 Hz, 4 H), 3.02 (d, J = 11.7 Hz, 1 H), 2.47 (s, 3 H), 1.37 (s, 1 
H), 0.54 – 0.52 (m, 1 H)  0.45 (t, J = 8.5 Hz, 3 H), -0.00 (s, 2 H) 
ppm. 13C NMR (75 MHz, CDCl3) δ 143.6, 129.7, 129.6, 126.9, 120.7, 
114.9, 74.4, 58.7, 40.0, 34.2, 29.3, 21.4, 8.5, 6.8, 4.7, 4.6 ppm. 
HRMS (FAB) Calcd for [C18H23NO3S] : 333.1399, found: 333.1397 
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17b: 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.1 Hz, 2 H), 7.33 (d, 
J = 13.9 Hz, 2 H), 6.32 (ddd, J = 8.8, 13.5, 18.6 Hz, 1 H), 6.19 – 
6.13 (m, 2 H), 5.44 (dd, J = 8.3, 15.1 Hz, 1 H), 5.21 (d, J = 16.9 Hz, 
1 H), 5.10 (d, J = 10.2 Hz, 1 H), 4.32 (dd, J = 1.0, 14.6 Hz, 1 H), 
4.00 (dd, J = 1.8, 15.0 Hz, 1 H), 3.64 – 3.61 (m, 1 H), 3.47 – 3.45 
(m, 1 H), 2.85 (t, J = 8.7 Hz, 1 H), 2.42 (s, 3 H), 2.03 (d, J = 8.9 
Hz, 2 H), 0.89 – 0.82 (m, 3 H) ppm 13C NMR (100 MHz, CDCl3) δ 
143.4, 134.7, 129.6, 128.2, 127.8, 127.7, 127.3, 126.7, 118.6, 116.7, 
54.9, 49.7, 47.8, 21.4, 20.0, 12.6 ppm. HRMS (EI) calc. for 
[C18H23NO2S]: 317.1450, found: 317.1447 
17c: 1H NMR (300 MHz, CDCl3) δ 7.51 (d, J = 7.8 Hz, 2 H), 7.19 (d, 
J = 7.6 Hz, 2 H), 6.20 (d, J = 8.0 Hz, 1 H), 5.20 (d, J = 8.1 Hz, 1 H), 
3.74 (d, J = 11.9 Hz, 1 H), 2.87 (d, J = 11.7 Hz, 1 H), 2.32 (s, 3 H), 
1.39 (dd, J = 7.2, 14.3 Hz, 1 H), 1.32 – 1.23 (m, 1 H), 0.94 (bs, 1 
H), 0.83 (t, J = 7.2 Hz, 3 H), 0.29 - 0.22 (m, 3 H), -0.05 (bs, 1 H), 
-0.21 (s, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.7, 135.2, 
129.9, 127.2, 120.6, 117.0, 40.7, 35.6, 30.2, 25.4, 23.4, 21.7, 12.0, 
9.0, 5.0, 4.8 ppm.  
18b: 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.2 Hz, 2 H), 7.34 (d, 
J = 7.7 Hz, 2 H) , 6.27 (td, J = 10.2, 16.8 Hz, 1 H), 6.09 (dd, J = 
10.5, 15.0 Hz, 1 H), 5.39 – 5.30 (m, 1 H), 5.17 (d, J = 16.6 Hz, 1 H), 
5.06 (d, J = 10.6 H z, 1 H), 4.97 (d, J = 2.1 Hz, 1 H), 4.86 (dd, J = 
2.2, 4.5 Hz, 1 H), 4.0 1 (d, J = 14.5 Hz, 1 H), 3.72 (dd, J = 1.8, 14.2 
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Hz, 1 H), 3.63 (dd, J = 8.0, 9.3 Hz, 1 H), 3.31 – 3.21 (m, 1 H), 2.85 
(t, J = 9.1 Hz, 1 H), 2.44 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3) δ 
146.8, 136.1, 133.9, 131.0, 129.7, 127.8, 127.4, 117.2, 114.9, 108.4, 
53.3, 51.8, 46.6, 21.5 ppm. HRMS (EI) calc. for [C16H19NO2S]: 
289.1137, found: 289.1133 
18d: 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J = 8.2 Hz, 2 H), 7.38 (d, 
J = 8.0 Hz, 2H), 6.35 (d, J = 8.0 Hz, 1H), 5.48 (dd, J = 5.5, 7.9 Hz, 
1 H), 3.93 (d, J = 11.7 Hz, 1 H), 3.04 (dd, J = 2.8, 11.8 Hz, 1 H), 
2.50 (s, 3 H), 1.39 – 1.32 (m, 1 H), 1.03 -0.97 (m, 1 H), 0.67 – 
0.60 (m, 1 H), 0.55 – 0.51 (m, 1 H), 0.39 (d, J = 8.2 Hz, 2 H), -
0.01 (d, J = 4.7 Hz, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.8, 
135.0, 129.9, 127.2, 120.9, 112.4, 40.6, 29.8, 24.3, 21.2, 13.4, 11.7, 
3.6, 3.4 ppm. 
19d: 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J = 8.1 Hz, 2 H), 7.38 (d, 
J = 7.9 Hz, 2 H), 6.33 (d, J = 8.1 Hz, 1 H), 5.32 (d, J = 8.1 Hz, 1 H), 
3.91 (d, J = 11.8 Hz, 1 H), 3.07 (dd, J = 2.3, 11.8 Hz, 1 H), 2.51 (s, 
3 H), 1.23 (s, 3 H), 1.11 – 1.0 (m, 1 H), 0.50 (bs, 2 H), 0.45 – 0.42 
(m, 1 H), 0.25 – 0.24 (m, 1 H), 0.00 - -0.01 (m, 2 H) ppm. 13C 
NMR (75 MHz, CDCl3) δ 143.7, 135.0, 129.8, 127.1, 119.6, 118.9, 
40.4, 34.9, 30.8, 21.7, 18.1, 8.9, 4.7, 4.5 ppm.  
20b: 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.3 Hz, 2 H), 7.32 (d, 
J = 8.0 Hz, 2 H), 5.45 (ddd, J = 8.3, 10.9 , 16.2 Hz, 1 H), 5.22 – 
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5.17 (m, 1 H), 5.07 (s, 1 H), 5.04 (dd, J = 0.9, 7.3 Hz, 1 H), 3.93 – 
3.88 (m, 1 H), 3.66 (dd, J = 1.5, 14.1 Hz, 1 H), 3.57 (dd, J = 7.6, 
9.3 Hz, 1 H), 3.21 – 3.16 (m, 1 H), 2.78 (t, J = 9.0 Hz, 1 H) , 2.42 
(s, 3 H), 1.53 (ddd, J =2 .0, 3.7, 4.9 Hz, 3 H) ppm. 13C NMR (75 
MHz, CDCl3) δ 143.5, 137.8, 136.3, 132.7, 129.6, 127.8, 118.4, 
117.5, 53.1, 49.4, 47.5, 21.5, 14.4 ppm. 
20d: 1H NMR (300 MHz, CDCl3) δ 7.62 (d, J = 8.2 Hz, 2 H), 7.29 (d, 
J = 8.1 Hz, 2 H), 6.24 (d, J = 8.2 Hz, 1 H), 5.18 (d, J = 8.2 Hz, 1 H), 
3.86 (d, J = 11.3 Hz, 1 H), 2.91 (dd, J = 2.7, 11.4 Hz, 1 H), 2.40 (s, 
3 H), 1.03 (s, 3 H), 0.93 (d, J = 6.3 Hz, 6 H), 0.85 – 0.83 (m, 1 H), 
0.63 – 0.57 (m, 1 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.7, 135.0. 
129.9, 127.2, 119.9, 118,3 40.6, 32.5, 26.3, 21.7, 17.3, 16.4, 13.1 
ppm.  
20f :1H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 7.9 Hz, 2 H), 7.32 (d, 
J = 7.8 Hz, 2 H), 6.45 (dd, J = 10.9, 17.5 Hz, 1 H), 5.11 (d, J = 
10.9 Hz, 1 H), 4.96 (d, J = 17.5 Hz, 1 H), 4.21 (s, 2 H), 4.09 (s, 2 
H), 2.43 (s, 3 H), 2.17 (dd, J = 7.51, 15.1 Hz, 2 H), 0.96 (t, J = 7.6 
Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.4, 137.3, 135.2, 
134.1, 129.7, 128.6, 127.4, 115.2, 57.2, 54.8, 21.5, 19.4, 12.5 ppm. 
HRMS (EI) calc. for [C15H19NO2S]:277.1137, found: 277.1134 
21d: 1H NMR (300 MHz, CDCl3) δ 7.67 (d, J = 8.1 Hz, 2 H) 7.31 -
7.96 (m, 5 H), 6.98 (d, J = 7.2 Hz, 2 H), 6.41 (d, J = 8.1 Hz, 1 H), 
5.31 (d, J = 8.1 Hz, 1 H), 4.03 (d, J 11.6 Hz, 1 H), 3.14 (dd, J = 2.6, 
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11.6 Hz, 1 H), 2.40 (s, 3 H), 1.90 (d, J = 5.9 Hz, 1 H), 1.81 (s, 1 H), 
0.85 (s, 3 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.9, 137.4, 134.9, 
130.0,128.8, 128.2, 127.2, 126.3, 120.8, 117.5, 40.5, 36.0, 29.5, 
21.7, 20.5, 17.7 ppm.  
22b: 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.2 Hz, 2 H), 7.35 (d, 
J = 8.0 Hz, 2 H), 5.70 (ddd, J = 7.1, 12.1, 17.2, 1H), 5.07 (dd, J = 
9.8, 13.5Hz, 3 H), 4.10 (d, J = 14.6 Hz, 1 H), 3.80 (d, J = 13.8 Hz, 
1 H), 3.49 (t, J = 6.5 Hz, 1 H), 3.50 – 3.38 (m, 1 H), 3.16 (dd, J = 
6.7, 9.4 Hz, 1 H), 2.45 (s, 3 H), 1.49 – 1.43 (m, 1 H), 0.78 – 0.69 (m, 
4 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.8, 135.2, 132.2, 129.7, 
127.9, 127.4, 115.8, 52.9, 50.1, 46.6, 21.5, 15.3, 5.8, 5.3 ppm. 
HRMS (FAB) calc. for [C17H21NO2S]: 303.1293, found: 329.1452- 
22d: 1H NMR (300 MHz, CDCl3) δ 7.55 (d, J = 8.2 Hz, 2 H), 7.23 (d, 
J = 8.1 Hz, 2 H), 6.17 (d, J = 8.2 Hz, 1 H), 5.18 (d, J = 8.2 Hz, 1 H), 
3.81 (d, J = 11.4 Hz, 1 H), 2.69 (dd, J = 2.3, 11.5 Hz, 1 H), 2.35 (s, 
3 H), 0.95 (d, J = 6.3 Hz, 3 H), 0.84 (d, J = 4.9 Hz, 1 H), 0.78 – 
0.77 (m, 1 H), 0.64 (dd, J = 6.0, 11.8 Hz, 1 H), 0.41- 0.26 (m, 2 H), 
0.01 – 0.00 (m, 2 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.7, 135.0, 
129.8, 127.2, 1198, 116.9, 40.7, 30.1, 26.2, 22.3, 21.7, 13.0, 11.8, 
3.8, 2.7 ppm.  
23d: 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 8.3 Hz, 2 H), 7.28 (d, 
J = 8.1 Hz, 2 H), 6.21 (d, J = 8.2 Hz, 1 H), 5.27 (d, J = 8.2 Hz, 1 H), 
3.82 (d, J = 11.9 Hz, 1 H), 2.83 (dd, J = 2.5, 12.0 Hz, 1 H), 2.41 (s, 
56 
 
3 H), 1.06 – 1.05 (m, 1 H), 1.02 – 0.95 (m, 1 H), 0.54 – 0.28 (m, 6 
H), 0.14 – 0.07 (m, 2 H), -0.07 – -0.17 (m, 2 H) ppm. 13C NMR (75 
MHz, CDCl3) δ 143.7, 135.1, 129.8, 127.1, 119.7, 117.4, 40.5, 36.1, 
29.3, 21.6, 12.5, 9.1, 5.1, 4.6, 3.7, 3.1 ppm. HRMS (FAB) calc. for 
[C19H23NO2S]: 329.1441, found: 329.1452 
24d: 1H NMR (300 MHz, CDCl3) δ 7.48 (d, J = 8.2 Hz, 2 H), 7.12 (d, 
J = 8.0 Hz, 2 H), 7.03 (d, J = 7.5 Hz, 3 H), 6.85 (d, J = 7.1 Hz, 2 H), 
6.21 (d, J = 8.2 Hz, 1 H), 5.09 (d, J = 8.2 Hz, 1 H), 3.85 (d, J   = 
11.6 Hz, 1 H), 2.83 (dd, J = 2.3, 11.7 Hz, 1 H), 2.22 (s, 3 H), 1.75 
(d, J = 5.9 Hz, 1 H), 1.67 (bs, 1 H), 0.33 – 0.27 (m, 1 H), 0.14 (dd, 
J = 6.0, 13.4 Hz, 1 H) , -0.02 - -0.03 (m, 2 H), -0.06 - -0.10 (m, 
1 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.9, 137.6, 134.9, 130.0, 
128.9, 1280, 127.2, 126.1, 120.9, 115.3, 40.6, 36.8, 29.4, 25.9, 21.7, 
12.6, 4.2, 2.8 ppm.  
25d: 1H NMR (300 MHz, CDCl3) δ 7.62 (d, J = 8.2 Hz, 2 H), 7.30 (d, 
J = 8.0 Hz, 2 H), 6.26 (d, J = 8.1 Hz, 1 H), 5.43 – 5.39 (m, 2 H), 
3.95 (d, J = 11.9 Hz, 1 H), 3.00 (dd, J = 2.1, 11.9 Hz, 1 H), 2.42 (s, 
3 H), 2.20 – 2.15 (m, 1 H), 1.96 (s, 3 H), 1.54 – 1.52 (m, 6 H), 0.34 
0.28 (m, 2 H), 0.25 – 0.21 (m, 1H) -0.12 - -0.13 (m, 2 H) ppm. 
13C NMR (75 MHz, CDCl3) δ 143.7, 136.7, 135.0, 129.9, 127.2, 
124.4, 119.5, 116.2, 40.5, 36.7, 29.0, 27.5, 25.4, 23.1, 22.6, 21.6, 
9.6, 5.0, 3.9 ppm.  
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26e: 1H NMR (300 MHz, CDCl3) δ7.60 (d, J = 8.1 Hz, 2 H), 7.24-
7.33 (m, 5 H), 7.14 (d, J = 6.9 Hz, 2 H,  0.86-0.98 (m, 1 H), 1.18-
1.26 (m, 2 H), 6.69 (d, J = 7.9 Hz, 1 H), 5.69 (d, J = 8.0 Hz, 1 H), 
4.03 (dd, J = 10.9, 4.5 Hz, 1 H), 2.75 (br s, 1 H), 2.61 (dd, J = 11.8, 
11.0 Hz, 1 H), 2.53-2.59 (m, 2 H), 2.42 (s, 3 H), 2.29 (dd, J = ~9.3, 
~9.0 Hz, 1 H), 1.70-1.88 (m, 4 H) ppm. 13C NMR (75 MHz, CDCl3) 
δ 143.6, 142.0, 135.9, 129.8, 128.6, 128.4, 127.7, 126.9, 126.6, 
125.2, 124.6, 103.9, 57.6, 53.7, 49.5, 47.9, 33.6, 25.7, 25.5, 25.3, 
21.5  
27e: 1H NMR (300 MHz, CDCl3) δ 7.60 (d, J = 8.2 Hz, 2 H), 7.27 (d, 
J = 7.9 Hz, 2 H), 7.06 (d, J = 8.6 Hz, 2 H), 6.84 (d, J = 8.5 Hz, 2 H), 
6.69 (d, J = 7.9 Hz, 1 H), 5.68 (d, J = 8.0 Hz, 1 H), 4.02 (dd, J = 
4.5, 10.8 Hz, 1 H), 3.82 (s, 3 H), 2.71 (d, J = 9.7 Hz, 1 H), 2.59 (t, 
J = 11.4 Hz, 1 H), 2.43 (s, 1 H) , 2.24 (t, 1H, J=9.2Hz) , 1.81 (m, 
1H) , 1.21 (dd, J=8.6Hz, J=19.1Hz, 1H) , 0.89 (t, J=9.1Hz, 1H) 
ppm.13C NMR (75 MHz, CDCl3) δ 158.5, 143.8, 136.1, 135.2, 134.1, 
130.0, 128.8, 127.2, 125.4, 124.9, 114.0, 104.1, 57.1, 55.5, 53.9, 
49.7, 48.2, 33.8, 25.9, 25.7, 25.5, 21.7 ppm.  
28d: 1H NMR (300 MHz, CDCl3) δ 7.67 (d, J = 8.1 Hz, 2 H), 7.30 (d, 
J = 8.1 Hz, 2 H), 6.90 (d, J = 8.6 Hz, 2 H), 6.78 (d, J = 8.6 Hz, 2 H), 
6.39 (d, J = 8.1 Hz, 1 H), 5.30 (d, J = 8.1 Hz, 1 H), 4.02 (d, J = 
11.5 Hz, 1 H), 3.78 (s, 3 H), 3.12 (dd, J = 2.6, 11.5 Hz, 1 H), 2.40 
(s, 3 H), 1.85 (d, J = 5.8 Hz, 1 H), 1.71 (d, J = 5.2 Hz, 1 H), 0.84 (s, 
3 H) ppm. 13C NMR (75 MHz, CDCl3) δ 158.2, 143.9, 134.9, 130.0, 
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129.8, 129.5, 127.3, 120.7, 11736, 113.7, 55.4, 40.6, 35.3, 29.7, 
21.7 20.2, 17.8 ppm.  
29d: 1H NMR (300 MHz, CDCl3) δ 7.66 (d, J = 7.8 Hz, 2 H), 7.29 (d, 
J = 7.7 Hz, 2 H), 6.90 (d, J = 8.1 Hz, 2 H), 6.76 (d, J = 7.9 Hz, 2 H), 
6.46 (d, J = 8.1 Hz, 1 H), 5.36 (d, J = 8.1 Hz, 1 H), 4.03 (d, J = 
11.6 Hz, 1 H), 3.77 (s, 3 H), 3.10 (d, J = 11.5 Hz, 1 H), 2.39 (s, 3 
H), 1.84 (d, J = 5.5 Hz, 1 H), 1.76 (s, 1 H), 1.25 -1.18 (m, 1 H), 
0.94 (m, 0.97 – 0.90, 1 H), 0.73 (t, J = 7.1 Hz, 3 H) ppm. 13C NMR 
(75 MHz, CDCl3) δ  ppm. HRMS (EI) calc. for [C22H25NO3S]: 
383.1555, found: 383.1552 
30d: 1H NMR (300 MHz, CDCl3) δ 7.66 (d, J=7.7Hz, 2 H) 7.28 (d, J 
= 7.9 Hz, 2 H), 6.89 (d, J = 8.1 Hz, 2 H), 6.77 (d, J = 7.9 Hz, 2 H), 
6.44 (d, J = 8.0 Hz, 1 H), 5.34 (d, J = 8.1 Hz, 1 H), 4.04 (d, J = 
11.6 Hz, 1 H), 3.76 (s, 3 H), 3.11 (d, J = 11.6 Hz, 1 H), 2.39 (s, 
3H), 1.78 – 1.76 (m, 2 H), 1.22 (s, 4 H), 0. 71 – 0.67 (m, 3 H) ppm. 
13C NMR (75 MHz, CDCl3) δ 158.2, 143.9, 135.1, 130.0, 129.7, 
129.5, 127.2, 121.4, 116.4, 113.6, 55.4, 40.7, 35.4, 40.7, 35.4, 33.7, 
29.0, 25.0, 21.7, 20.6, 14.3 ppm. HRMS (EI) calc. for [C23H27NO3S]: 
397.1712, found: 397.1712 
32d: 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J = 7.4 Hz, 2 H), 7.34 (d, 
J = 7.8 Hz, 2 H), 7.00 (d, J = 8.1 Hz, 2 H), 6.81 (d, J = 7.8 Hz, 2 H), 
6.41 (d, J = 8.2 Hz, 1 H), 5.30 (d, J = 8.2 Hz, 1 H), 4.07 (d, J = 
11.5 Hz, 1 H), 3.81 (s, 3 H), 3.04 (dd, J = 1.8 Hz, 11.5 Hz, 1 H), 
2.44 (s, 3 H), 1.93 (d, J = 5.8 Hz, 1 H), 1.81 (d, J=4.9 Hz, 1 H), 
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0.51 – 0.47 (m, 1 H), 0.37 -0.33 (m, 1 H), 0.23 - 0.19 (m, 2 H), 
0.13 – 0.09 (m, 1 H) ppm. 13C NMR (75 MHz, CDCl3) δ 158.1, 143.9, 
135.0, 130.0, 129.9, 129.6, 127.2, 120.8, 115.3, 113.5, 55.4, 40.6, 
36.1, 29.4, 25.5, 21.7, 12.7, 4.1, 2.8 ppm. HRMS (EI) calc. for 
[C23H25NO3S]: 395.1555, found: 395.1558 
33d: 1H NMR (300 MHz, CDCl3) δ 7.67 (d, J = 8.0 Hz, 2 H), 7.29 (d, 
J = 8.2 Hz, 2 H), 6.92 (d, J = 8.3 Hz, 2 H), 6.75 (d, J = 8.4 Hz, 2 H), 
6.50 (d, J = 8.2 Hz, 1 H), 5.62 (d, J = 8.2 Hz, 1 H), 4.03 (d, J = 
11.3Hz, 1H), 3.78 (s, 3 H), 3.09 (dd, J = 2.1, 11.4 Hz, 1 H), 2.39 (s, 
3 H), 1.90 – 1.78 (m, 5 H), 1.61 (d, J = 9.5 Hz, 2 H), 1.55 (s, 2 H) 
ppm. 13C NMR (75 MHz, CDCl3) δ 158.1, 143.9, 135.0, 130.0(6), 
130.0(1), 129.5, 127.2, 121.8, 113.5, 113.3, 55.4, 40.9, 37.7, 35.5, 
28.6, 27.0, 25.7, 24.7, 21.7, 18.4 ppm. HRMS (FAB) [M + H]+ calc. 
for [C24H27NO3S]
 :409.1712, found: 410.1791 
34d: 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 8.2 Hz, 2 H). 7.33 (d, 
J = 8.2 Hz, 2 H), 6.85 (d, J = 8.7 Hz, 2 H), 6.64 (d, J = 8.6 Hz, 2 H), 
6.54 (d, J = 8.7 Hz, 2 H), 6.41 – 6.38 (m, 3 H),. 5.43 (d, J = 8.1 Hz, 
1 H), 4.17 (d, J = 11.9 Hz, 1 H), 3.69 (s, 3 H), 3.66 (s, 3 H), 3.30 
(dd, J = 2.4, 12.0 Hz, 1 H), 2.44 (s, 3 H), 2.32 (d, J = 5.8 Hz, 1 H), 
1.94 (d, J = 6.1 Hz, 1 H) ppm. 13C NMR (100 MHz, CDCl3) δ 158.0, 
157.6, 143.8, 134.7, 131.4, 130.7, 129.9, 129.0, 128.3, 127.0, 119.7, 
118.0, 113.6, 113.0, 55.0(9), 55.0(6), 40.2, 37.1, 31.0(7), 31.0(0), 




35d: 1H NMR (300 MHz, CDCl3) δ 7.83 (d, J= 8.2 Hz, 2 H), 7.51 – 
7.46 (m, 7 H), 6.59 (d, J = 8.1 Hz, 1 H), 5.54 (d, J = 8.1 Hz, 1 H), 
4.16 (d, J = 11.5 Hz, 1 H), 3.19 (d, J = 11.5 Hz, 1 H), 2.61 (s, 3 H), 
1.19 (d, J = 4.8 Hz, 1 H), 1.14 (d, J = 4.6 Hz, 1 H), 0.72 – 0.65 (m, 
1 H), 0.59 -0.54 (m, 1 H), 0.34 – 0.28 (m, 1 H), 0.12 – 0.06 (m, 1 
H), 0.04 - -0.03 (m, 1 H) ppm. 13C NMR (75 MHz, CDCl3) δ 143.9, 
139.3, 135.0, 130.0(8), 130.0(6), 128.5, 127.2, 121.4, 115.8, 48.2, 
40.2, 24.3, 21.7, 20.6, 14.0, 3.0 ppm.  
36d: 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.2 Hz, 2 H), 7.30 (d, 
J = 8.2 Hz, 2 H), 7.23 – 7.19 (m, 2 ). 6.95 (t, J = 8.6Hz, 2 H), 6.38 
(d, J = 8.1 Hz, 1 H), 5.32 (d, J = 8.1 Hz, 1 H),  3.92 (d, J = 11.6 
Hz, 1 H), 2.94 (d, J = 11.6 Hz, 1 H), 2.41 (s, 3 H), 0.96 (d, J = 4.9 
Hz, 1 H), 0.88 – 0.86 (m, 1 H), 0.49 – 0.44 (m, 1 H), 0.40 – 0.33 (m, 
1 H), 0.14 – 0.08 (m, 1 H), -0.05 - -0.13 (m, 1 H), -0.20 - -0.26 
(m, 1 H) ppm. 13C NMR (100 MHz, CDCl3) δ 143.7, 134.8, 131.4, 
131.3, 129.8, 127.0, 121.2, 115.5, 115.3, 115.1, 48.0, 39.2, 24.1, 
21.5, 20.5, 13.7, 2.8(6), 2.8(5) ppm. 
37c: 1H NMR (300 MHz, CDCl3) δ 7.64 (d, J = 8.1 Hz, 2 H), 7.31 (d, 
J = 8.0 Hz, 2 H), 7.13 (d, J = 8.5 Hz, 2 H), 6.83 (d, J = 8.5 Hz, 2 H), 
6.35 (d, J = 8.0 Hz, 1 H), 5.34 (d, J = 8.0 Hz, 1 H), 3.94 (d, J = 
11.4 Hz, 1 H), 3.78 (s, 3 H), 2.92 (d, J = 11.4 Hz, 1 H), 2.43 (s, 3 
H), 1.18 (d, J = 4.5 Hz, 1 H), 0.91 (d, J = 4.4 Hz, 1 H), 0.85 (s, 3 
61 
 
H) ppm. 13C NMR (75 MHz, CDCl3) δ 158.8, 143.9, 135.0, 131.1, 
131.0, 129.9, 127.2, 120.8, 118.3, 114.0, 55.4, 48.3, 39.1, 24.4, 
21.7, 20.9, 18.9 ppm.  
38c: 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.3 Hz, 2 H), 7.30 (d, 
J = 8.0 Hz, 2 H), 7.23 – 7.19 (m, 2 H), 6.95 (ddd, J = 2.5, 5.9, 10.7 
Hz, 2 H), 6.37 (dd, J = 0.9, 8.1 Hz, 1 H), 5.32 (d, J = 8.1 Hz, 1 H), 
3.92 (dd, J = 1.0, 11.6 Hz, 1 H), 2.93 (d, J = 11.6 Hz, 1 H), 2.41 (s, 
3 H), 0.96 (d, J = 4.9 Hz, 1 H), 0.88 (d, J = 4.9 Hz, 1 H), 0.51 – 
0.44 (m, 1 H), 0.40 – 0.33 (m, 1H)  0.11 (td, J = 5.6, 9.4Hz, 1 H), 
-0.07 - -0.12 (m, 1 H), -0.25 – 0.26 (m, 1 H) ppm. 13C NMR (75 
MHz, CDCl3) δ 143.7, 134.8, 131.4, 131.3, 129.8, 127.0, 121.2, 
115.5, 115.3, 115.1, 48.0, 39.2, 24.1, 21.5, 20.5, 13.7 ppm 
39d: 1H NMR (300 MHz, CDCl3) δ 7.01 (d, J = 8.5 Hz, 2 H), 6.74 (d, 
J = 8.4 Hz, 2 H), 6.19 (d, J = 6.0 Hz, 1 H), 5.11 (d, J = 6.0 Hz, 1 H), 
4.17 (d, J = 10.3 Hz, 1 H), 3.78 (d, J = 10.3 Hz, 1 H) 3.71 (s, 3 H), 
2.34 (d, J = 5.7 Hz, 1 H), 1.63 (d, J = 5.3 Hz, 1 H), 1.23 - 1.16 (m, 
1 H), 0.94 – 0.85 (m, 1 H), 0.75 (t, J = 7.2 Hz, 3 H) ppm. 13C NMR 
(75 MHz, CDCl3) δ 158.1, 142.0, 130.3, 129.9, 113.6, 109.8, 62.1, 
55.4, 35.3, 27.9, 24.7, 11.4 ppm. HRMS (FAB) calc. for [C15H16O2]: 
230.1307, found: 230.1301 
40d: 1H NMR (300 MHz, CDCl3) δ 7.07 (d, J = 8.4 Hz, 2 H), 6.82 (d, 
J = 8.4 Hz, 2 H), 6.24 (d, J = 5.9 Hz, 1 H), 5.17 (d, J = 5.9 Hz, 1 H), 
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4.25 (d, J = 10.3 Hz, 1 H), 3.87 (d, J = 10.3 Hz, 1 H), 3.79 (s, 3 H), 
2.38 (d, J = 5.6 Hz, 1 H), 1.72 (d, J = 4.9 Hz, 1 H), 1.37 – 1.26 (m, 
4 H), 0.78 (t, J = 6.9 Hz, 3 H) ppm. 13C NMR (75 MHz, CDCl3) δ 
158.1, 141.7,  130.3, 129.9, 113.6, 110.3, 62.0, 55.4, 35.0, 33.9, 














Single crystal diffraction data were measured by a Bruker-Nonius 
CCD single-crystal X-ray diffractometer at room temperature by 
using graphite-monochromated Mo K radiation ( = 0.71073 Å). 
Preliminary orientation matrices and unit cell parameters were 
obtained from the peaks of the first 10 frames and then refined using 
the whole data set. Frames were integrated and corrected for 
Lorentz and polarization effects using DENZO. The structure was 
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solved by direct methods using SHELXS-97, and refined by full-
matrix least-squares with SHELXL-97. All non-hydrogen atoms 
were refined anisotropically and all hydrogen atoms were treated as 
idealized contributions. 
Crystal data for 17d: C18H23NO2S (293K). M = 503.63, triclinic, 
space group P1, a = 10.4402 (9) Å, b = 12.7247(11) Å, c = 
13.2229(9) Å, β = 84.852(5)°, V = 1711.9(2) Å3, Z = 4, calc. = 
1.232 g/cm-3, absorption coefficient = 0.196 mm-1, total reflections 
collected 7763, unique 3134 (Rint = 0.0000), GOF = 1.101, R1 = 
0.0994, Rw = 0.3239 (I>2(I)). 
Crystal data for 34d: C27H27NO4S (293K). M = 503.63, monoclinic, 
space group P21/c, a = 14.3764(5) Å, b = 6.4364(3) Å, c = 
25.7893(11) Å, β = 91.356(2)°, V = 2385.67 (17) Å3, Z = 4, calc. = 
1.285 g/cm-3, absorption coefficient = 0.169 mm-1, total reflections 
collected 5285, unique 2962 (Rint = 0.0348), GOF = 1.017, R1 = 
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팔라듐을 촉매로 한 1,6-인아인 물질에 대한 고리이성질화 반응은 꾸준
히 연구되어 오고 있다. 그 물질들은 다양한 고리화물질들로 쉽게 합성 
될 수 있다. 우리는 바이닐 사이클로 프로필기가 치환된 1,6인아인 물질
의 이탈기에 따른 고리화반응을 연구하였다. 포스페이트 이탈기가 치환된 
인아인은 5.7-바이사이클릭트라이엔, 알콕시 이탈기가 치환된 인아인은 
모노사이클릭 트라이엔 반응이 진행되었다. 그리고 1,6-인아인이 팔라듐 
존재하에 좋은 수득률로 바이사이클로[4.1.0]헵테인으로 고리이성질화되
는 것을 연구하였다 
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닐사이클로프로페, 고리이성질화 
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